Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions

ABSTRACT

The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Oct. 8, 2012, isnamed DI200221.txt and is 122,056 bytes in size.

The invention relates to recombinant measles viruses expressing epitopesof antigens of RNA viruses including especially retroviruses andflaviviruses and to their use for the preparation of vaccinecompositions.

Measles virus is a member of the order mononegavirales, i.e., viruseswith a non-segmented negative-strand RNA genome. The non segmentedgenome of measles virus (MV) has an antimessage polarity which resultsin a genomic RNA which is not translated either in vivo or in vitro norinfectious when purified.

Transcription and replication of non-segmented (−) strand RNA virusesand their assembly as virus particles have been studied and reportedespecially in Fields virology (3^(rd) edition, vol. 1, 1996,Lippincott—Raven publishers—Fields B N et al). Transcription andreplication of measles virus do not involve the nucleus of the infectedcells but rather take place in the cytoplasm of said infected cells. Thegenome of the measles virus comprises genes encoding six majorstructural proteins from the six genes (designated N, P, M, F, H and L)and an additional two-non structural proteins from the P gene. The geneorder is the following: 3′-I, N, P (including C and V), M, F, H, and Llarge polymerase protein at the 5′ end. The genome further comprises noncoding regions in the intergenic region M/F; this non-coding regioncontains approximately 1000 nucleotides of untranslated RNA. The citedgenes respectively encode the leader peptide (I gene), the proteins ofthe nucleocapsid of the virus, i.e., the nucleoprotein (N), thephosphoprotein (P), and the large protein (L) which assemble around thegenome RNA to provide the nucleocapsid. The other genes encode theproteins of the viral envelope including the hemagglutinin (H), thefusion (F) and the matrix (M) proteins.

The measles virus has been isolated and live attenuated vaccines havebeen derived from the Edmonston M V isolated in 1954 (Enders, J. F., andT. C. Peebles. 1954. Propagation in tissue cultures od cytopathogenicagents from patients with measles. Proc. Soc. Exp. Biol. Med.86:277-286.), by serial passages on primary human kidney or amnioncells. The used strains were then adapted to chick embryo fibroblasts(CEF) to produce Edmonston A and B seeds (Griffin, D., and W. Bellini.1996. Measles virus, p. 1267-1312. In B. Fields, D. Knipe, et al. (ed.),Virology, vol. 2. Lippincott—Raven Publishers, Philadelphia). EdmonstonB was licensed in 1963 as the first MV vaccine. Further passages ofEdmonston A and B on CEF produced the more attenuated Schwarz andMoraten viruses (Griffin, D., and W. Bellini. 1996. Measles virus, p.1267-1312. In B. Fields, D. Knipe, et al. (ed.), Virology, vol. 2.Lippincott—Raven Publishers, Philadelphia) whose sequences have recentlybeen shown to be identical (Parks, C. L., R. A. Lerch, P. Walpita, H. P.Wang, M. S. Sidhu, and S. A. Udem. 2001. Analysis of the noncodingregions of measles virus strains in the Edmonston vaccine lineage. JVirol. 75:921-933; Parks, C. L., R. A. Lerch, P. Walpita, H. P. Wang, M.S. Sidhu, and S. A. Udem. 2001. Comparison of predicted amino acidsequences of measles virus strains in the Edmonston vaccine lineage. JVirol. 75:910-920). Because Edmonston B vaccine was reactogenic, it wasabandoned in 1975 and replaced by the Schwarz/Moraten vaccine which iscurrently the most widely used measles vaccine in the world (Hilleman,M. 2002. Current overview of the pathogenesis and prophylaxis of measleswith focus on practical implications. Vaccine. 20:651-665). Severalother vaccine strains are also used: AIK-C, Schwarz F88, CAM70, TD97 inJapan, Leningrad-16 in Russia, and Edmonston Zagreb. The CAM70 and TD97Chinese strains were not derived from Edmonston. Schwarz/Moraten andAIK-C vaccines are produced on CEF. Zagreg vaccine is produced on humandiploid cells (WI-38).

The live attenuated vaccine derived from the Schwarz strain iscommercialized by Aventis Pasteur (Lyon France) under the trademarkROUVAX®.

In a noteworthy and pioneer work, Martin Billeter and colleagues clonedan infectious cDNA corresponding to the antigenome of Edmonston MV andestablished an original and efficient reverse genetics procedure torescue the corresponding virus (Radecke, F., P. Spielhofer, H.Schneider, K. Kaelin, M. Huber, K. Dötsch, G. Christiansen, and M.Billeter., 1995. Rescue of measles viruses from cloned DNA. EMBOJournal. 14:5773-5784) and WO 97/06270. They developed an Edmonstonvector for the expression of foreign genes (Radecke, F., and M.Billeter. 1997. Reverse genetics meets the nonsegmented negative-strandRNA viruses. Reviews in Medical Virology. 7:49-63.) and demonstrated itslarge capacity of insertion (as much as 5 kb) and its high stability atexpressing transgenes (Singh, M., and M. Billeter. 1999. A recombinantmeasles virus expressing biologically active human interleukin-12. J.Gen. Virol. 80:101-106; Singh, M., R. Cattaneo, and M. Billeter. 1999. Arecombinant measles virus expressing hepatitis B virus surface antigeninduces humoral immune responses in genetically modified mice. J. Virol.73:4823-4828; Spielhofer, P., T. Bachi, T. Fehr, G. Christiansen, R.Cattaneo, K. Kaelin, M. Billeter, and H. Naim. 1998. Chimeric measlesviruses with a foreign envelope. J. Virol. 72:2150-2159); Wang, Z., T.Hangartner, L. Cornu, A. Martin, M. Zuniga, M. Billeter, and H. Naim.2001. Recombinant measles viruses expressing heterologus antigens ofmumps and simian immunodeficiency viruses. Vaccine. 19:2329-2336. Thisvector was cloned from the Edmonston B strain of MV propagated in HeLacells (Ballart, I., D. Eschle, R. Cattaneo, A. Schmid, M. Metzler, J.Chan, S. Pifko-Hirst, S. A. Udem, and M. A. Billeter. 1990. Infectiousmeasles virus from cloned cDNA. Embo J. 9:379-384).

In addition, recombinant measles virus expressing Hepatitis B virussurface antigen has been produced and shown to induce humoral immuneresponses in genetically modified mice (Singh M. R. et al, 1999, J.virol. 73: 4823-4828).

MV vaccine induces a very efficient, life-long immunity after a singlelow-dose injection (10⁴ TCID₅₀) (33,34). Protection is mediated both byantibodies and by CD4+ and CD8+ T cells. The MV genome is very stableand reversion to pathogenicitiy has never been observed with thisvaccine. MV replicates exclusively in the cytoplasm, ruling out thepossibility of integration in host DNA. Furthermore, an infectious cDNAclone corresponding to the anti-genome of the Edmonston strain of MV anda procedure to rescue the corresponding virus have been established(35). This cDNA has been made into a vector to express foreign genes(36). It can accommodate up to 5 kb of foreign DNA and is geneticallyvery stable (37, 38, 39).

From the observation that the properties of the measles virus andespecially its ability to elicit high titers of neutralizing antibodiesin vivo and its property to be a potent inducer of long lasting cellularimmune response, the inventors have proposed that it may be a goodcandidate for the preparation of compositions comprising recombinantinfectious viruses expressing antigenic peptides or polypeptides ofdetermined RNA viruses, including especially retroviruses orflaviviruses, to induce neutralizing antibodies against said RNA virusand especially said retroviruses or flaviviruses which preferably couldbe suitable to achieve at least some degree of protection against saidRNA viruses, especially retroviruses or flaviviruses, in animals andmore preferably in human hosts. Especially, MV strains and in particularvaccine strains have been elected in the present invention as candidatevectors to induce immunity against both measles virus and RNA viruswhose constituent is expressed in the designed recombinant MV, inexposed infant populations because they are having no MV immunity. Adultpopulations, even already MV immunized individuals, may however alsobenefit from MV recombinant immunization because re-administering MVvirus under the recombinant form of the present invention may result ina boost of anti-MV antibodies.

Among retroviruses of interest, the inventors have chosen AIDSretroviruses, including HIV-1 and among flaviviruses, some which areimportant human pathogens such as Yellow Fever Virus (YFV) and West NileVirus (WNV).

The YFV and WNV belong to the family Flaviviridae described in Fieldsvirology (3^(rd) edition, vol. 1, 1996, Lippincott—Ravenpublishers—Fields B N et al).

The invention relates to a ecombinant mononegavirales virus expressing aheterologous amino acid sequence, said recombinant virus being capableof eliciting a humoral and/or a cellular immune response against saidheterologous amino acid sequence including in individuals havingpre-existing measles virus immunity.

In a first embodiment, the invention especially provides recombinantmeasles viruses capable of expressing antigens and especially epitopesderived from antigens of RNA viruses including retroviruses orflaviviruses.

The invention also relates to nucleic acid constructs especially torecombinant nucleic acid constructs expressing the recombinant measlesviruses and expressing therewith antigens or epitopes of antigens ofretroviruses or flaviviruses.

The invention concerns also processes for the preparation of suchrecombinant measles viruses and especially relates to the production ofsuch recombinant MV in rescue systems.

The invention is also directed to compositions comprising saidrecombinant measles viruses as active principles for protection ofhosts, especially human hosts, against diseases related to infections bysaid retroviruses, especially by AIDS retroviruses, or saidflaviviruses, especially Yellow Fever Virus or West Nile Virus.

Nucleic acid sequences of Measles Viruses have been disclosed inInternational Patent Application WO 98/13501, especially a DNA sequenceof 15,894 nucleotides corresponding to a DNA copy of the positive strand(antigenomic) message sense RNA of various wild-type of vaccine measlesstrains, including Edmonston Wild-type strain, Moraten strain andSchwarz strain which is identical to the Moraten strain except fornucleotide positions 4917 and 4924 where Schwarz strain has a «C»instead of a «T».

In order to produce recombinant measles viruses, a rescue system hasbeen developed for the Edmonston MV strain and described inInternational Patent Application WO 97/06270. The description of saidrescue system contained in WO 97/06270 is incorporated herewith byreference, and reference is made especially to the examples of thisInternational application, including the Examples related to cells andviruses, to generation of cell line 293-3-46, plasmid constructions,transfection of plasmids and harvest of reporter gene products,experimental set-up to rescue MV, helper cells stably expressing MV Nand P proteins as well as T7 RNA polymerase, MV rescue using helpercells 293-3-46 and characterization of rescued MV.

The rescue system disclosed in WO 97/06270 has been further developed toinclude a heat-shock step described in Parks C. L. et al, 1999, J.virol. 73: 3560-3566. The disclosure of this enhanced measles virus cDNArescue system is incorporated herewith by reference.

The invention thus relates to recombinant measles viruses expressing aheterologous amino acid sequence derived from an antigen of a determinedRNA virus, especially from a retrovirus or flavivirus, wherein saidrecombinant measles virus is capable of eliciting a humoral and/or acellular immune response against measles virus or against said RNAvirus, especially retrovirus or flavivirus or against both measles virusand against said RNA virus, especially retrovirus or flavivirus.

The expression «heterologous amino acid sequence» is directed to anamino acid sequence which is not derived from the antigens of measlesviruses, said heterologous amino acid sequence being accordingly derivedfrom a RNA virus, especially from a retrovirus or flavivirus of interestin order to establish an immune response in a host, especially in ahuman and preferably to establish protection against an infection bysaid RNA virus, especially retrovirus or flavivirus.

The heterologous amino acid sequence expressed in recombinant measlesviruses according to the invention is such that it is capable ofeliciting a humoral and/or cellular immune response in a determinedhost, against the RNA virus, especially retrovirus or flavivirus fromwhich it originates. Accordingly, this amino acid sequence is one whichcomprises at least one epitope of an antigen, especially a conservedepitope, which epitope is exposed naturally on the antigen or isobtained or exposed as a result of a mutation or modification orcombination of antigens.

Antigens used for the preparation of the recombinant measles viruses areespecially envelope antigens of RNA viruses such as retroviruses orflaviviruses, especially from envelopes of AIDS viruses including HIV-1or from envelopes of the Yellow Fever Virus or envelopes from the WestNile Virus. Other retroviral or flaviviral antigens may however beadvantageously used in order to derive recombinant measles virusescapable of eliciting antibodies against said retroviruses orflaviviruses, and the invention relates in a particular embodiment toantigens from which amino acid sequences can be derived which elicit theproduction of neutralizing antibodies against the retrovirus orflavivirus. According to another embodiment of the invention, amino acidsequence of these antigens alternatively or additionally also elicits acellular immune response against the retrovirus or flaviviruses.

Advantageously, the recombinant measles virus of the invention alsoelicits a humoral and/or cellular immune response against measles virus.This response is however not mandatory provided the immune responseagainst the RNA virus, especially retrovirus or flavivirus is indeedobtained.

According to a preferred embodiment of the invention, the recombinantmeasles virus of the invention is obtained within a rescue system forthe preparation of infectious measles viruses. Accordingly, therecombinant measles virus is a rescued infectious measles virusrecovered from a rescue system.

A particular recombinant measles virus of the invention is derived fromthe Edmonston strain of measles virus.

Another particular and preferred recombinant measles virus according tothe invention is derived from the Schwarz strain and especially from anapproved vaccine Schwarz strain such as that produced under thetrademark ROUVAX®, available from Aventis Pasteur (France).

The invention thus provides for a recombinant measles virus which isrecovered from helper cells transfected with a cDNA encoding theantigenomic RNA ((+)strand) of the measles virus, said cDNA beingrecombined with a nucleotide sequence encoding the RNA viral, especiallyretroviral or flaviviral, heterologous amino acid sequence.

The expression «encoding» in the above definition encompasses thecapacity of the cDNA to allow transcription of a full length antigenomic(+)RNA, said cDNA serving especially as template for transcription.Accordingly, when the cDNA is a double stranded molecule, one of thestrands has the same nucleotide sequence as the antigenomic (+) strandRNA of the measles virus, except that «U» nucleotides are substituted by«T» in the cDNA. Such a cDNA is for example the insert corresponding tothe measles virus, contained in the pTM-MVSchw plasmid deposited underNo 1-2889 at the COLLECTION NATIONALE DE CULTURES DE MICROORGANISMES(CNCM), 25 rue du Docteur Roux, F-75724 Paris Cedex 15, France on Jun.12, 2002. This plasmid is represented on FIG. 2A.

The expression “cDNA” used for the description of the nucleotidesequence of the molecule of the invention merely relates to the factthat originally said molecule is obtained by reverse transcription ofthe full length genomic (−)RNA genome of viral particles of the measlesvirus.

This should not be regarded as a limitation for the methods used for itspreparation. The invention thus encompasses, within the expression“cDNA”, every DNA provided it has the above defined nucleotide sequence.Purified nucleic acids, including DNA are thus encompassed within themeaning cDNA according to the invention, provided said nucleic acid,especially DNA fulfils the above-given definitions.

The helper cells according to the rescue system are transfected with atranscription vector comprising the cDNA encoding the full lengthantigenomic (+)RNA of the measles virus, when said cDNA has beenrecombined with a nucleotide sequence encoding the heterologous aminoacid sequence of interest (heterologous nucleotide sequence) and saidhelper cells are further transfected with an expression vector orseveral expression vectors providing the helper functions includingthose enabling expression of trans-acting proteins of measles virus,i.e., N, P and L proteins and providing expression of an RNA polymeraseto enable transcription of the recombinant cDNA and replication of thecorresponding viral RNA.

The invention relates in particular to the preparation of recombinantmeasles viruses bearing epitopes of antigens of HIV retroviruses. Itencompasses especially a recombinant measles virus expressing aheterologous amino acid sequence which is derived from an envelopeantigen of HIV and which is especially derived from an envelope proteinor glycoprotein of HIV-1.

The antigens of interest in this respect are especially gp160, gp120 andgp41 of HIV-1 or gp140, GAG or TAT of HIV-1.

In a particular embodiment of the invention, the heterologous amino acidsequence is derived from a recombinant gp160, gp120 of HIV-1 or gp140,GAG or TAT of HIV-1.

The invention is directed in particular to a recombinant measles viruswherein the V1, V2 and/or V3 loops of the gp120 (or gp160) antigen aredeleted or deleted in part, individually or in combination in such a waythat conserved epitopes are exposed on the obtained recombinant gp120antigen.

The V1, V2 and V3 loops of the gp120 (or gp160) antigen of HIV-1 havebeen especially disclosed in Fields virology (Fields B. N. etal—Lippincott Raven publishers 1996, p. 1953-1977).

According to another embodiment of the invention, the recombinantmeasles virus is such that it expresses a heterologous amino acidsequence derived from the gp120 (or gp160) antigen of HIV-1, wherein theV1, V2 and/or V3 loops of the gp120 (or gp160) antigen are substitutedor substituted in part, individually or in combination, in such a waythat conserved epitopes are exposed on the obtained recombinant gp120(or gp160) antigen.

According to another particular embodiment, the recombinant measlesvirus expressing a heterologous DNA sequence derived from an envelopeantigen of HIV-1 is derived from the gp120 antigen in such a way thatthe V1 and V2 loops are deleted and the V3 loop is substituted for thesequence AAELDKWASAA (SEQ ID NO: 8).

According to another particular embodiment of the invention, therecombinant measles virus is one expressing an heterologous amino acidsequence selected among gp160ΔV3, gp160ΔV1V2, gp160ΔV1V2V3, gp140ΔV3,gp140ΔV1V2, gp140ΔV1V2V3, which heterologous amino acid sequences areschematically represented on FIG. 1.

The invention also relates to recombinant measles viruses as definedaccording to the above statements, wherein the amino acid sequence isderived from an antigen of the Yellow Fever virus selected among theenvelope (Env) or the NS1 proteins or immunogenic mutants thereof.

The invention also relates to recombinant measles viruses as definedaccording to the above statements, wherein the amino acid sequence isderived from an antigen of the West Nile virus selected among theenvelope (E), premembrane (preM) or immunogenic mutants thereof.

The invention also relates to recombinant measles viruses or to viruslike particles (VLP) which express double or multiple recombinantantigens, especially multiple HIV antigens (including fragments thereof)or flavivirus antigens, against which an immune response is sought. Suchrecombinant measles viruses or VLP may advantageously express antigensfrom different viruses and thus provide immunogens against variousviruses.

The invention further relates to recombinant measles viruses accordingto anyone of the above definitions, wherein the cDNA required for theexpression of the viral particles, which is comprised within the EdB-tagvirus vector or preferably within the pTM-MVSchw vector is recombinedwith the ATU sequence of FIG. 8, said ATU being inserted in a positionof the EdB-tag vector or of the pTM-MVSchw vector taking advantage ofthe gradient of the viral genome to allow various levels of expressionof the transgenic sequence encoding the heterologous amino acid sequenceinserted in said ATU. The invention advantageously enables the insertionof such heterologous DNA sequences in a sequence which is designated anAdditional Transcription Unit (ATU) especially an ATU as disclosed byBilleter et al in WO 97/06270.

The advantageous immunological properties of the recombinant measlesviruses according to the invention can be shown in an animal model whichis chosen among animals susceptible to measles viruses and wherein thehumoral and/or cellular immune response against the heterologous antigenand/or against the measles virus is determined.

Among such animals suitable to be used as model for the characterizationof the immune response, the skilled person can especially use mice andespecially recombinant mice susceptible to measles viruses, or inmonkeys.

In a preferred embodiment of the invention, the recombinant measlesvirus of the invention is suitable to elicit neutralizing antibodiesagainst the heterologous amino acid sequence in a mammalian animal modelsusceptible to measles virus. Especially, this immune responsecomprising elicitation of neutralizing antibodies can be sought inrecombinant mice or monkeys.

According to another particular embodiment of the invention, especiallywhen the heterologous amino acid sequence is derived from one of theenvelope proteins of HIV-1 and where it elicits antibodies capable ofneutralizing a primary HIV isolate, the response is advantageouslytested on indicater cells such as P4-CCR5 cells available from the NIH(NIH AIDS Research and Reference Reagent Program). (Charneau P. etal—1994—J. Mol. Biol. 241: 651-662).

According to another preferred embodiment, the recombinant measles virusaccording to the invention elicits neutralizing antibodies against theheterologous amino acid sequence in a mammal, with a titre of at least1/40000 when measured in ELISA, and a neutralizing titre of at least1/20.

The invention also relates to a recombinant measles virus nucleotidesequence comprising a replicon comprising (i) a cDNA sequence encodingthe full length antigenomic (+)RNA of measles virus operatively linkedto (ii) an expression control sequence and (iii) a heterologous DNAsequence coding for a determined heterologous amino acid sequence, saidheterologous DNA sequence being cloned in said replicon in conditionsallowing its expression and in conditions not interfering withtranscription and replication of said cDNA sequence, said repliconhaving a total number of nucleotides which is a multiple of six.

A particular cDNA sequence is the sequence of the cDNA of the Schwarzstrain depicted on FIG. 11. Such a cDNA can be obtained from pTM-MVSchw.

pTM-MVSchw is a plasmid derived from Bluescript containing the completesequence of the measles virus, vaccine strain Schwarz, under the controlof the promoter of the T7 RNA polymerase. Its size is 18967nt.

The invention concerns also a recombinant measles virus vectorcomprising the above defined recombinant measles virus nucleotidesequence.

The «rule of six» is expressed in the fact that the total number ofnucleotides present in the recombinant cDNA resulting from recombinationof the cDNA sequence derived from reverse transcription of theantigenomic RNA of measles virus, and the heterologous DNA sequencefinally amount to a total number of nucleotides which is a multiple ofsix, a rule which allows efficient replication of genome RNA of themeasles virus.

A preferred recombinant measles virus vector according to the abovedefinition is such that the heterologous DNA virus vector wherein theheterologous DNA sequence is cloned within an Additional TranscriptionUnit (ATU) inserted in the cDNA corresponding to the antigenomic RNA ofmeasles virus.

The additional transcription unit (ATU) is disclosed on FIG. 2A; it canbe modified provided it ultimately enables the obtained replicon in thevector to comply with the rule of six.

The location of the ATU within the cDNA derived from the antigenomic RNAof the measles virus can vary along said cDNA. It is however located insuch a site that it will benefit from the expression gradient of themeasles virus.

This gradient corresponds to the mRNA abundance according to theposition of the gene relative to the 3′ end of the template.Accordingly, when the polymerase operates on the template (eithergenomic and anti-genomic RNA or corresponding cDNAs), it synthetizesmore RNA made from upstream genes than from downstream genes. Thisgradient of mRNA abondance is however relatively smooth for measlesvirus. Therefore, the ATU or any insertion site suitable for cloning ofthe heterologous DNA sequence can be spread along the cDNA, with apreferred embodiment for an insertion site and especially in an ATU,present in the N-terminal portion of the sequence and especially withinthe region upstream from the L-gene of the measles virus andadvantageously upstream from the M gene of said virus and morepreferably upstream from the N gene of said virus.

Depending on the expression site and the expression control of theheterologous DNA, the vector of the invention allows the expression ofthe heterologous amino acid sequence as a fusion protein with one of themeasles virus proteins.

Alternatively, the insertion site of the DNA sequence in the cDNA of themeasles virus can be chosen in such a way that the heterologous DNAexpresses the heterologous amino acid sequence in a form which is not afusion protein with one of the proteins of the measles virus.

The recombinant measles virus vector according to any of the preferreddefinitions contains advantageously a heterologous DNA sequence whichencodes a retroviral, a flaviviral amino acid sequence.

As an example, this amino acid sequence is derived from an antigen of aretrovirus selected among HIV retroviruses, or a flavivirus, especiallythe Yellow Fever virus or the West Nile virus.

In a particular embodiment of the invention, the heterologous amino acidsequence encoded by the recombinant measles virus vector is derived froman envelope antigen of an HIV retrovirus, especially from HIV-1.

In a preferred embodiment, this amino acid sequence encoded by theheterologous DNA sequence is selected among the gp160, the gp120 or gp41of HIV-1, or the gp140 of HIV-1, or a mutated version of said antigens.

As one result which is expected by expressing the recombinant measlesvirus vector of the invention is the elicitation of an immune response,especially a humoral and/or cellular immune response, against theheterologous amino acid sequence encoded by the vector, it is preferredthat the heterologous DNA sequence used is one which codes for anantigen or a mutated antigen which enables exposition of neutralizingepitopes on the produced expression product of said vector.

In a particular embodiment, the heterologous amino acid sequenceexpressed, can expose epitopes which are not accessible or not formed inthe native antigen from which the heterologous amino acid sequencederives.

In a preferred embodiment of the invention, the heterologous DNAsequence encodes gp160ΔV3, gp160ΔV1V2, gp160ΔV1V2V3, gp140ΔV3,gp140ΔV1V2, gp140ΔV1V2V3.

Heterologous amino acid sequences are especially disclosed on FIG. 1 andcan be prepared according to well-known methods starting from sequencesof antigens or corresponding DNA sequences of said antigens obtainedfrom various HIV-1 isolates.

According to a preferred embodiment of the invention, the recombinantmeasles virus vector is designed in such a way that the particlesproduced in helper cells transfected or transformed with said vectorcontaining the DNA encoding the full length antigenomic (+)RNA ofmeasles virus, originated from a measles virus strain adapted forvaccination, enable the production of viral particles for use inimmunogenic compositions, preferably protective or even vaccinecompositions.

Among measles virus strains adapted for vaccination, one can cite theEdmonston B. strain and the Schwarz strain, the latter being preferredand distributed by the company Aventis Pasteur (Lyon France) as anapproved vaccination strain of measles virus.

The nucleotide sequences of the Edmonston B. strain and of the Schwarzstrain, have been disclosed in WO 98/13505.

In order to prepare the recombinant measles virus vector of theinvention, the inventors have designed plasmid pTM-MVSchw which containsthe cDNA resulting from reverse transcription of the antigenomic RNA ofmeasles virus and an adapted expression control sequence including apromoter and terminator for the T7 polymerase.

The recombinant measles virus vector according to the invention ispreferably a plasmid.

Preferred vectors are those obtained with the nucleotide sequence of theEdmonston B. strain deposited on Jun. 12, 2002 especially:

-   -   pMV2(EdB)gp160[delta]V3HIV89.6P CNCM I-2883    -   pMV2(EdB)gp160HIV89.6P CNCM I-2884    -   pMV2(EdB)gp140HIV89.6P CNCM I-2885    -   pMV3(EdB)gp140[delta]V3HIV89.6P CNCM I-2886    -   pMV2(EdB)-NS1YFV17D CNCM I-2887    -   pMV2(EdB)-EnvYFV17D CNCM I-2888.

Other preferred vectors are those obtained with the nucleotide sequenceof the Schwarz strain, deposited at the CNCM on May 26, 2003:

-   -   pTM-MVSchw2-Es(WNV) CNCM I-3033    -   pTM-MVSchw2-GFPbis- CNCM I-3034    -   pTM-MVSchw2-p17p24[delta]myr(HIVB) CNCM I-3035    -   pTM-MVSchw3-Tat(HIV89-6p) CNCM I-3036    -   pTM-MVschw3-GFP CNCM I-3037    -   pTM-MVSchw2-Es (YFV) CNCM I-3038 and the vectors deposited at        the CNCM on Jun. 19, 2003:    -   pTM-MVSchw2-gp140 [delta] V1 V2 V3 (HIV89-6) CNCM I-3054    -   pTM-MVSchw2-gp140 [delta] V3 (HIV89-6) CNCM I-3055    -   pTM-MVSchw2-gp160 [delta] V1 V2 V3 (HIV89-6) CNCM I-3056    -   pTM-MVSchw2-gp160 [delta] V1 V2 (HIV89-6) CNCM I-3057    -   pTM-MVSchw2-Gag SIV239 p17-p24 [delta] myr-3-gp140 (HIV89-6)        CNCM I-3058.

I-2883 (pMV2(EdB)gp160[delta]V3HIV89.6P) is a plasmid derived fromBluescript containing the complete sequence of the measles virus(Edmonston strain B), under the control of the T7 RNA polymerasepromoter and containing the gene of the gp160ΔV3+ELDKWAS (residues 3-9of SEQ ID NO: 8) of the virus SVIH strain 89.6P inserted in an ATU atposition 2 (between the N and P genes of measles virus). The size of theplasmid is 21264nt.

I-2884 (pMV2(EdB)gp160HIV89.6P) is a plasmid derived from Bluescriptcontaining the complete sequence of the measles virus (Edmonston strainB), under the control of the T7 RNA polymerase promoter and containingthe gene of the gp160 of the SVIH virus strain 89.6P inserted in an ATUat position 2 (between the N and P genes of measles virus). The size ofthe plasmid is 21658 nt.

I-2885 (pMV2(EdB)gp140HIV89.6P) is a plasmid derived from Bluescriptcontaining the complete sequence of the measles virus (Edmonston strainB), under the control of the T7 RNA polymerase promoter and containingthe gene of the gp140 of the SVIH virus strain 89.6P inserted in an ATUat position 2 (between the N and P genes of measles virus). The size ofthe plasmid is 21094 nt.

I-2886 (pMV3(EdB)gp140[delta]V3HIV89.6P) is a plasmid derived fromBluescript containing the complete sequence of the measles virus(Edmonston strain B), under the control of the T7 RNA polymerasepromoter and containing the gene of the gp140ΔV3(ELDKWAS; residues 3-9of SEQ ID NO: 8) of the SVIH virus strain 89.6P inserted in an ATU atposition 2 (between the N and P genes of measles virus). The size of theplasmid is 21058 nt.

I-2887 (pMV2(EdB)-NS1YFV17D) is a plasmid derived from Bluescriptcontaining the complete sequence of the measles virus (Edmonston strainB), under the control of the T7 RNA polymerase promoter and containingthe NS1 gene of the Yellow Fever virus (YFV 17D) inserted in an ATU atposition 2 (between the N and P genes of measles virus). The size of theplasmid is 20163 nt.

I-2888 (pMV2(EdB)-EnvYFV17D) is a plasmid derived from Bluescriptcontaining the complete sequence of the measles virus (Edmonston strainB), under the control of the T7 RNA polymerase promoter and containingthe Env gene of the Yellow Fever virus (YFV 17D) inserted in an ATU atposition 2 (between the N and P genes of measles virus). The size of theplasmid is 20505 nt.

I-3033 (pTM-MVSchw2-Es(WNV) is a plasmid derived from Bluescriptcontaining a cDNA sequence of the complete infectious genome of themeasles virus (Schwarz strain), under the control of the T7 RNApolymerase promoter and expressing the gene of the secreted envelope,(E) of the West Nile virus (WNV), inserted in an ATU.

I-3034 (pTM-MVSchw2-GFPbis) is a plasmid derived from Bluescriptcontaining a cDNA sequence of the complete infectious genome of themeasles virus (Schwarz strain), under the control of the T7 RNApolymerase promoter and expressing the gene of the GFP inserted in anATU.

I-3035 (pTM-MVSchw2-p17p24[delta]myr(HIVB) is a plasmid derived fromBluescript containing a cDNA sequence of the complete infectious genomeof the measles virus (Schwarz strain), under the control of the T7 RNApolymerase promoter and expressing the gene of the gag gene encodingp17p24Δmyrproteins of the HIVB virus inserted in an ATU.

I-3036 (pTMVSchw3-Tat(HIV89-6p) is a plasmid derived from Bluescriptcontaining a cDNA sequence of the complete infectious genome of themeasles virus (Schwarz strain), under the control of the T7 RNApolymerase promoter and expressing the gene of the Tat gene of the virusstrain 89.6P inserted in an ATU.

I-3037 (pTM-MVSchw3-GFP) is a plasmid derived from Bluescript containinga cDNA sequence of the complete infectious genome of the measles virus(Schwarz strain) under the control of the T7 RNA polymerase promoter andexpressing the gene of the GFP gene inserted in an ATU having a deletionof one nucleotide.

I-3038 (pTM-MVSchw2-Es) (YFV) is a plasmid derived from Bluescriptcontaining a cDNA sequence of the complete infectious genome of themeasles virus (Schwarz strain) under the control of the T7 RNApolymerase promoter and expressing the gene of the secreted protein ofthe Fever virus (YFV) inserted in an ATU.

I-3054 (pTM-MVSchw2-gp140 [delta] V1 V2 V3 (HIV89-6)) is a plasmidderived from Bluescript containing a cDNA sequence of the completeinfectious genome of the measles virus (Schwarz strain), under thecontrol of the T7 RNA polymerase promoter and expressing the geneencoding gp140 [delta] V1 V2 (HIV 89-6) inserted in an ATU.

I-3055 (pTM-MVSchw2-gp140 [delta] V3 (HIV89-6)) is a plasmid derivedfrom Bluescript containing a cDNA sequence of the complete infectiousgenome of the measles virus (Schwarz strain), under the control of theT7 RNA polymerase promoter and expressing the gene encoding gp14 [delta]V3 (HIV 89-6) inserted in an ATU.

I-3056 (pTM-MVSchw2-gp160 [delta] V1 V2 V3 (HIV89-6)) is a plasmidderived from Bluescript containing a cDNA sequence of the completeinfectious genome of the measles virus (Schwarz strain), under thecontrol of the T7 RNA polymerase promoter and expressing the geneencoding gp160 [delta] V1 V2 V3 (HIV 89-6) inserted in an ATU.

I-3057 (pTM-MVSchw2-gp160 [delta] V1 V2 (HIV89-6)) is a plasmid derivedfrom Bluescript containing a cDNA sequence of the complete infectiousgenome of the measles virus (Schwarz strain), under the control of theT7 RNA polymerase promoter and expressing the gene encoding gp160[delta] V1 V2 (HIV 89-6) inserted in an ATU.

I-3058 (pTM-MVSchw2-Gag SIV239 p17-p24 [delta] myr-3-gp140 (HIV89-6)) isa plasmid derived from Bluescript containing a cDNA sequence of thecomplete infectious genome of the measles virus (Schwarz strain), underthe control of the T7 RNA polymerase promoter and expressing the geneencoding Gag SIV239 p17-p24 [delta] myr-3-gp140 (HIV89-6) inserted in anATU.

In a particular embodiment of the invention, the replicon contained inthe recombinant measles virus vector is designed according to the map ofFIG. 2 wherein «insert» represents the heterologous DNA sequence.

When the heterologous DNA sequence present in the recombinant measlesvirus vector of the invention is derived from the Yellow Fever Virus(YFV), it is advantageously selected among YFV 17D 204 commercialized byAventis Pasteur under the trademark STAMARIL®.

When the heterologous DNA sequence present in the recombinant measlesvirus vector of the invention is derived from the West Nile Virus (WNV),it is advantageously selected among the neurovirulente strain IS 98-ST1.

The invention also relates to a rescue system for the assembly ofrecombinant measles virus expressing a heterologous amino acid sequence,which comprises a determined helper cell recombined with at least onevector suitable for expression of T7 RNA polymerase and expression ofthe N, PandL proteins of the measles virus transfected with arecombinant measles virus vector according to anyone of the definitionsprovided above.

The recombinant viruses of the invention or the VLP can also be producedin vivo by a live attenuated vaccine like MV.

The recombinant viruses of the invention or the VLP can be used inimmunogenic compositions or in vaccine compositions, for the protectionagainst RNA viruses, which antigens are expressed in the recombinantvirus or in the VLP, as disclosed above and illustrated in the followingexamples.

The invention especially provides for immunogenic compositions or forvaccine compositions useful against HIV virus, West Nile virus or YellowFever virus.

The invention also concerns the use of the recombinant viruses disclosedor of the VLP, or of the recombinant vectors, for the preparation ofimmunogenic compositions or for the preparation of vaccine compositions.

The invention also relates to antibodies prepared against saidrecombinant viruses or against said VLP, especially to protectiveantibodies and to neutralizing antibodies. Antibodies may be polyclonalantibodies, or monoclonal antibodies.

The recombinant viruses of the invention or the VLP can be associatedwith any appropriate adjuvant, or vehicle which may be useful for thepreparation of immunogenic compositions.

Various aspects of the invention will appear in the examples whichfollow and in the drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B. HIV1 Env glycoprotein constructions. (A) gp160constructions full-length and ΔV3-AAELDKWASAA (SEQ ID NO: 8), ΔV1V2 andΔV1V2V3 (SEQ ID NO: 8) mutants (from top to bottom). The BbsI and MfeIrestriction sites used to introduce the ΔV3 deletion in the otherconstructions are indicated. (B) gp140 constructions are the same asgp160 except that the intracytoplasmic and transmembrane regions of thegp41 have been deleted (AAELDKWASAA disclosed as SEQ ID NO: 8).

FIG. 2A. Schematic map of the pTM-MV Schw plasmid. To construct thecomplete sequence, the six fragments represented in the upper part weregenerated and recombined step by step using the unique restriction sitesindicated. T7=T7 promoter; hh=hammerhead ribozyme; hAv=hepatitis deltaribozyme (=δ); T7t=T7 RNA polymerase terminator.

FIG. 2B. The pMV(+) vectors with ATU containing a green fluorescentprotein (GFP) gene in position 2 and position 3. The MV genes areindicated: N (nucleoprotein), PVC (phosphoprotein and V C proteins), M(matrix), F (fusion), H (hemaglutinin), L (polymerase). T7: T7 RNApolymerase promoter; T7t: T7 RNA polymerase terminator; δ: hepatitisdelta virus (HDV) ribozyme; ATU: additional transcription unit.

ATU sequence: small letters represent additional sequences (copy of theN-P intergenic region of measles virus) plus cloning sites. Capitalletters correspond to the inserted enhanced GFP sequence. This sequenceis inserted at the SpeI site (position 3373) of the cDNA sequence of theSchwarz strain of the measles virus for ATU2 and at the SpeI site(position 9174) for the ATU3. The mutation which distinguishes normalATU from bis (in pTM-MVSchw2-gfp and pTM-MVSchw2-GFPbis) is asubstituted C (Capital letter) at the end of ATU.

FIG. 3A: shows that ENV_(HIV89.6) expression was similar for passages 2and 5, confirming the stability of expression of transgenes in thissystem.

FIG. 3B: Construct of double recombinant pTM-MVSchw2-Gag-3gp140

Some recombinant vectors expressing two different heterologous antigenshave been constructed. They were obtained by ligation of two differentrecombinant pTM-MVSchw plasmids containing different inserts in position2 and position 3. Plasmid pTM-MVSchw2-Gag-3-gp140 is shown. From thisplasmid a recombinant virus was rescued that expressed both Gag andgp140 proteins (FIG. 3B(2) Western blot). Using appropriateconstructions of the different inserted heterologous genes, suchrecombinant MV expressing two heterologous viral proteins may produce«virus like particles» (VLP) assembled in infected cells and secreted:Gag-Env from retroviruses or prM/E from flaviviruses. Such VLP are goodimmunogens. Produced in vivo by a live attenuated vaccine like MV, theyshould be even more immunogenic.

FIG. 3C: Expression of HIV-1 envelope glycoproteins in recombinantpTM-MVSchw. Vero cells were infected with the different recombinantviruses for 48H and expression of HIV Env was determined by westernblot. 30 μg of each cell lysate were resolved on 4-12% SDS-PAGE, blottedonto nitrocellulose membranes and probed with a mouse monoclonalanti-HIV gp120 (Chessie, NIH) antibody. Anti-mouse IgG RPO conjugate wasused as second antibody and proteins were detected using an ECLdetection kit.

FIG. 3D: Expression of HIV-1 gp140 and SIV239 Gag in recombinantpTM-MVSchw2-Gag_(SIV) (p17-p24 [delta] myr)-3-gp140_(HIV). HIV gp140 andSIV Gag were detected in lysates of infected Vero cells. (A) a mousemonoclonal anti-HIV gp120 and (B) serum from macaque infected withSIVmac251.

FIG. 3E: Expression of HIV-1 Gag (p17-p24 Δmyr) in recombinantpTM-MVSchw2-Gag_(m) (p17-p24 [delta] myr). HIV Gag were detected inlysates of infected Vero cells with a mouse monoclonal anti-HIV Gagantibody.

FIG. 3F: Expression of HIV-1 Tat protein in recombinant pTM-MVSchw. Verocells were infected with MVSchw-Tat HIV recombinant or control MVSchwviruses for 48H and expression of HIV Tat was determined by westernblot. 30 μg of each cell lysate were resolved on 4-12% SDS-PAGE, blottedonto nitrocellulose membranes and probed with a mouse monoclonalanti-HIV Tat (BH10, NIH) antibody. Anti-mouse IgG RPO conjugate was usedas second antibody and proteins were detected using an ECL detectionkit.

FIGS. 4A and 4B. Growth kinetics of recombinant MV_(EdB)-Env_(HIV)viruses on Vero cells. Cells on 35 mm dishes were infected withrecombinant viruses at different MOI (as indicated). At each time point,cells were collected and cell-associated virus titers were determinedusing the TCID₅₀ method on Vero cells. (A) Infections with MV EdB-tagand different MV-HIV recombinant viruses at MOI=0.0001. (B) Infectionswith MV2-gp160_(HIV) at two different MOI (0.0001 and 0.01).

FIGS. 5A through 5F. Anti-HIV and anti-MV humoral immune responses inmice inoculated with recombinant MV_(EdB)-Env_(HIV) viruses. A-B Fourgroups of 3 mice were immunized with 10⁷ TCID₅₀ of each MV-HIVrecombinant virus. Antibody titers against MV (A) and HIV Env (B) weredetermined by ELISA in sera collected 28 days post inoculation. C-F:Anti-HIV and anti-MV antibody titers in IFNAR^(−/−)/CD46^(+/−) miceimmunized with MV-Env_(HIV) viruses. (C) Anti-MV and anti-HIV titersdetected 28 days after injection of increasing doses of MV_(EdB)-gp160(3 mice per group). (D) Anti-MV (black bars), anti-HIV (gray bars) andanti-ELDKWAS (Residues 3-9 of SEQ ID NO: 8; white bars) titers detected28 days after injection of 5 106 TCID₅₀ of MV-Env_(HIV) viruses (6 miceper group). Results are expressed as the mean values±SD.

FIG. 6. Neutralizing activities against Bx08 of sera from mice immunizedwith MV2-gp140_(HIV89.6) and MV2-gp160_(HIV89.6) viruses. Primaryisolate Bx08 was provided by C.Moog (Strasbourg, France) and propagatedonce on PHA-stimulated PBMC to obtain viral stocks. 2 ng of virus wasincubated for 30 min at 37° C. with 25 μl of each mouse serum (collectedone month post-infection) before infection of P4R5 cells in a 96-wellplate. Cells were then cultured in DMEM containing 10% of fetal calfserum until 2 days post-infection, at wich time ß Galactosidase activitywas measured with a chemiluminescence test (Roche, Germany). Lane 1:serum of a MV_(EdB)-Tag immunized mouse; Lane 2: serum of aMV2-gp140_(HIV-1) immunized mouse; Lane 3: serum of a MV2-gp160_(HIV-1)immunized mouse; Lane 4: non-infected cells. All assays were performedin triplicate.

FIGS. 7A through 7D. Edm-HIV Env vaccine candidate stimulatesenv-specific lymphocytes in vivo. Two groups of 3 mice were inoculatedwith 10⁷ TCID₅₀ of MV2-gp160_(HIV) virus, and euthanized 7 day and one 1month post inoculation. (A) ELISpot assays performed with splenocytesfrom immunized mice. Stimulation with HIV-gp120 purified protein (black)or irrelevant BSA (white). (B) Splenocytes collected 7 days afterimmunization were stimulated either with medium alone (left panel), HIVgp120 (middle panel) or EdB-tag virus (right panel). Three-colorcytofluorometry detected both CD8+ (upper panel) and CD4+ (lower panel)lymphocytes producing γ-IFN after HIV gp120 and measles virusstimulations. Percentages are given according to the total CD8+ (upperpanel) and CD4+ (lower panel) lymphocyte gates respectively. (C and D).Anti-MV and anti-HIV antibody titers in mice and macaques immunized withMV2-gp140HIV89.6 virus months after MV priming. (C) Mice (3 per group)were vaccinated with 10⁵ TCID₅₀ of EdB-tag MV then inoculated twice with5 10⁶ TCID₅₀ of MV2-gp140_(HIV89.6) virus as indicated (arrows). (D)Cynomolgus macaques (#432 and 404) were vaccinated with ROUVAX® theninoculated twice with 5 10⁶ TCID₅₀ of MV2(gp140_(HIV89.6) virus asindicated (arrows).

FIGS. 8A and 8B. Schematic representation the additional transcriptionunit (ATU) (Residues 1817-1843 of SEQ ID NO: 16 and 3475-3498 of SEQ IDNO: 16, respectively, in order of appearance) and Schwarz MV vectorplasmid. (A) Cis-acting elements of the ATU inserted in position 2between phosphoprotein (P) and matrix (M) MV open reading frames. (B).Representation of the three positions of ATU insertion in the Schwarz MVvector plasmid.

FIG. 9. Expression of YFV proteins b y recombinant MV. Vero cells wereinfected by recombinant EdB-Env_(YFV) and EdB-NS1_(YFV) MV at an MOI of0.01. Immunofluorescence was performed using a mouse polyclonal anti-YFVserum and a Cy3 secondary anti-mouse IgG antibody. All the syncytiaobserved in infected Vero cells were positive.

FIG. 10. YFV challenge. Six 4-weeks old mice were inoculated with amixture of EdB-Env_(YFV) and EdB-NS1_(YFV) viruses (10⁷ TCID₅₀) and 6control mice were inoculated with the same dose of standard EdB-tagvirus. After 1 month, anti-MV serologies were determined and a similarlevel of antibodies was observed in the two groups. Mice were challengedand mortality was observed.

FIGS. 11A through 11E. Complete nucleotide sequence of the pTM-MVSchwplasmid (CNCM I-2889; SEQ ID NO: 16). The sequence can be described asfollows with reference to the position of the nucleotides:

  1-8 NotI restriction site   9-28 T7 promoter   29-82 Hammer headribozyme   83-15976 MV Schwarz antigenome 15977-16202 HDV ribozyme andT7 terminator 16203-16210 NotI restriction site 16211-16216 ApaIrestriction site 16220-16226 KpnI restriction site 16226-18967pBluescript KS(+) plasmid (Stratagene)

FIGS. 12A and 12B. (SEQ ID NO: 17):

The flaviral sequences which have been expressed in MV are thefollowing:

YFV Env seq: This is the Env YFV 17D204 sequence cloned by theinventors.

pos 1 à 3 START codon pos 4 à 51 Env signal peptide pos 52 à 1455 Envsequence pos 1456 à 1458 STOP codonThe stop and start codons have been added.

YFV NS1 seq: This is the NS1 YFV 17D204 sequence cloned by theinventors.

pos 1 à 3 START codon pos 4 à 78 NS1 signal peptide pos 79 à 1110 NS1sequence pos 1111 à{grave over ( )} 1113 STOP codonThe stop and start codons have been added.

FIG. 12C: WNV Env seq (SEQ ID NO: 18): this is the Env WNV sequencecloned by the inventors.

pos 1 à 3 START codon pos 4 à 51 env signal peptide pos 52 à 1485 Envsequence pos 1486 à 1488 STOP codonThe stop and start codons have been added.

FIG. 12D: WNV NS1 seq (SEQ ID NO: 19): This is the NS1 WNV sequencecloned by the inventors.

pos 1 à 3 START codon pos 4 à{grave over ( )} 78 NS1 signal peptide pos79 à 1104 NS1 sequence pos 1105 à 1107 STOP codon pos 1108 à 1110 STOPcodon (a second is added in order to respect the rule six.)The stop and start codons have been added.

FIG. 13: Schematic representation of recombinant pTM-MVSchw-sE_(WNV).The MV genes are indicated: N (nucleoprotein), PVC (phosphoprotein andV, C proteins), M (matrix), F (fusion), H (hemmaglutinin), L(polymerase). T7: T7 RNA polymerase promoter; T7t: T7 RNA polymeraseterminator; δ hepatitis delta virus (HDV) ribozyme; ATU: additionaltranscription unit.

After rescue, the recombinant virus was grown on Vero cell monolayers.The procedure used to prepare the recombinant virus was similar to thestandard procedures used to prepare the live attenuated measlesvaccines, except for the lyophilization that was not used.

The WNV sE expression in Vero cells infected by the MV-WN sE virus wasverified by using indirect immunofluorescence assay as shown in FIG. 14.

FIGS. 14A through 14D: Expression of sE protein from WNV in MV inducedsyncytia. Immunofluorescence detection of secreted WNV Env (sE) proteinin syncytia induced by recombinant MV-WN sE in Vero cells. (A, B) sEprotein detected at the external surface all around recombinantMV-induced syncytia. (C, D) intracellular sE protein in recombinantMV-induced syncytia.

FIG. 15: Anti-MV serology 1 month after the first injection.

FIGS. 16A through 16T: HIV-1 immunogenic sequences prepared forinsertion in plasmid pTM-MVSchw2 illustrated in Example II (SEQ ID NOS:24-43, respectively, in order of appearance).

EXAMPLE I: RECOMBINANT MEASLES VIRUSES EXPRESSING THE NATIVE ENVELOPEGLYCOPROTEIN OF HIV1 CLADE B, OR ENVELOPES WITH DELETED VARIABLE LOOPS,INDUCE HUMORAL AND CELLULAR IMMUNE RESPONSES

Preparing a vaccine against HIV with its formidable ability at evadingthe host immune responses is certainly a daunting task. However, what wehave learned about the immunopathogenesis of the infection and resultsalready obtained with animal models indicate that it may be possible(Mascola, J. R., and G. J. Nabel. 2001. Vaccines for prevention of HIV-1disease. Immunology. 13:489-495). Ideally, a preventive immunizationshould induce 1) antibodies that neutralize primary isolates, therebypreventing entry into host cells, and 2) CTL that eliminate the cellsthat were nevertheless infected. Antibodies and CTL should be directedat conserved epitopes that are critical for viral entry and replicationinto host cells.

Several studies, in particular with various candidate vaccines, showthat a good cellular immune response might be able to control viralload, although not to eliminate the agent (Mascola, J. R., and G. J.Nabel. 2001. Vaccines for prevention of HIV-1 disease. Immunology.13:489-495). On the other hand humoral immune responses induced so farby subunit vaccines have been disappointing, mainly because theantibodies induced did not neutralize primary isolates of HIV. Forexample, recombinant vaccines expressing the SIV Env were able toprotect macaques against an homologous, but not an heterologous,challenge (Hu, S., et al 1996. Recombinant subunit vaccines as anapproach to study correlates of protection against primate lentivirusinfection. Immunology Letters. 51:115-119). DNA immunization combinedwith boosting with soluble recombinant gp could protect macaques againstan heterologous challenge but only against a strain of SIV geneticallyrelated to the vaccine (Boyer, J. et al 1997. Protection of chimpanzeesfrom high-dose heterologous HIV-1 challenge by DNA vaccination. NatureMedicine. 3:526-532). More recently, various «prime-boost» regimen,using combinations of naked DNA and viral vectors such as MVA (Amara, R.et al. 2001. Control of a mucosal challenge and prevention of AIDS by amultiprotein DNA/MVA vaccine. Science. 292:69-74) or Adenovirus (Shiver,J. W., et al 2002. Replication-incompetent adenoviral vaccine vectorelicits effective anti- immunodeficiency-virus immunity. Nature.415:331-335), gave reasonable protection against a challenge withpathogenic SHIV89.6P. «Prime-boost» might not be an absolute requirementsince using recombinant live attenuated polio virus vaccine protectedmacaques against an SIV251 challenge (Crotty, S., et al 2001. Protectionagainst simian immunodeficiency virus vaginal challenge by using Sabinpoliovirus vectors. J Virol. 75:7435-7452). It is interesting to notethat in all these experiments, even when the animals were not protectedagainst the infection, immunization caused a delay in, or evenabrogated, clinical disease.

As shown by crystallography, the V1 and V2 loops of gp120 mask the CD4binding site and the V3 loop masks the binding sites for the CXCR4 andCCR5 co-receptors (Kwong, P. D., et al 2000. Structures of HIV-1 gp120envelope glycoproteins from laboratory-adapted and primary isolates.Structure Fold Des. 8:1329-1339; Kwong, P. D. et al 1998. Structure ofan HIV gp120 envelope glycoprotein in complex with the CD4 receptor anda neutralizing human antibody. Nature. 393:648-659; Kwong, P. D., et al2000. Oligomeric modeling and electrostatic analysis of the gp120envelope glycoprotein of human immunodeficiency virus. J Virol.74:1961-1972). In spite of this, antibodies against the gp120 CD4binding site are present in the sera of HIV seropositive individuals andare able to neutralize several HIV-1 isolates in in vitro tests (Burton,D. 1997. A vaccine for HIV type 1: the antibody perspective. Proceedingsof the National Academy of Sciences of the United States of America.94:10018-10023; Hoffman, T. L et al., 1999. Stable exposure of thecoreceptor-binding site in a CD4-independent HIV-1 envelope protein.Proc Natl Acad Sci USA. 96:6359-6364). Also, some epitopes which areburied in the 3-D structure of the glycoprotein but become exposed afterbinding to the co-receptor, can induce highly neutralizing antibodies(Muster, T., et al 1993. A conserved neutralizing epitope on gp41 ofhuman immunodeficiency virus type 1. J Virol. 67:6642-6647).Furthermore, neutralizing monoclonal antibodies have been obtained frompatient's B cells (Parren, P. W., et al 1997. Relevance of the antibodyresponse against human immunodeficiency virus type 1 envelope to vaccinedesign. Immunol Lett. 57:105-112). They are directed at gp41 linearepitopes (2F5) (Muster, T., F. et al 1993. A conserved neutralizingepitope on gp41 of human immunodeficiency virus type 1. J Virol.67:6642-6647), or at gp120 conformational epitopes (2G12, 17b, 48db12)(Thali, M., et al 1993. Characterization of conserved humanimmunodeficiency virus type 1 gp120 neutralization epitopes exposed upongp120-CD4 binding. J Virol. 67:3978-3988; Trkola, A., et al. 1996. Humanmonoclonal antibody 2G12 defines a distinctive neutralization epitope onthe gp120 glycoprotein of human immunodeficiency virus type 1. J Virol.70:1100-1108). Used in synergy they can neutralize in vitro severalprimary isolates (Mascola, J. R. et al 1997. Potent and synergisticneutralization of human immunodeficiency virus (HIV) type 1 primaryisolates by hyperimmune anti-HIV immunoglobulin combined with monoclonalantibodies 2F5 and 2G12. J Virol. 71:7198-7206) and protect macaquesagainst a mucosal challenge with SHIV (Baba, T. W et al, 2000. Humanneutralizing monoclonal antibodies of the IgG1 subtype protect againstmucosal simian-human immunodeficiency virus infection. Nat Med.6:200-206; Mascola, J. R., et al 1999. Protection of Macaques againstpathogenic simian/human immunodeficiency virus 89.6PD by passivetransfer of neutralizing antibodies. J Virol. 73:4009-4018; Mascola, J.R., et al 2000. Protection of macaques against vaginal transmission of apathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizingantibodies. Nat Med. 6:207-210). However in infected people, all theseantibodies are present in very low amounts, diluted in large quantitiesof non-neutralizing antibodies directed mainly at the antigenicallyvariable V1, V2 and V3 gp120 loops. Therefore, there is hope that if onecould induce high levels of such cross-neutralizing antibodies one mayachieve at least some degree of protection. A major goal is to design avector that will favor the production of such neutralizing antibodies.

For this reason, we engineered mutant gp160 (anchored) and gp140(soluble) by deleting the hypervariable V1, V2 and V3 loops individuallyor in combination to expose conserved epitopes and induce antibodiesable to neutralize primary isolates. In some of the constructions, wealso replaced the V3 loop by the AAELDKWASAA (SEQ ID NO: 8) sequence,especially ELDKWAS (SEQ ID NO: 8) sequence flanked on both sides by twoAlanine to maintain the conformation of this gp41 conserved epitopenormally buried in the native protein but able to induce large spectrumneutralizing antibodies (Muster, T., F. at al 1993. A conservedneutralizing epitope on gp41 of human immunodeficiency virus type 1. JVirol. 67:6642-6647; Binley, J. M., et al 2000. A recombinant humanimmunodeficiency virus type 1 envelope glycoprotein complex stabilizedby an intermolecular disulfide bond between the gp120 and gp41 subunitsis an antigenic mimic of the trimeric virion-associated structure. JVirol. 74:627-643; Sanders, R. W., et al 2000. Variable-loop-deletedvariants of the human immunodeficiency virus type 1 envelopeglycoprotein can be stabilized by an intermolecular disulfide bondbetween the gp120 and gp41 subunits. J Virol. 74:5091-5100). The normalalpha helical structure of this peptide should be conserved when exposedin our constructions at the tip of a deleted V3 loop. Theseconstructions, in which the “immunological decoys” have been eliminatedand the neutralizing epitopes have been exposed, should be goodcandidates for the induction of robust neutralizing antibody responses.

The HIV gp constructions were introduced into a measles vaccine vectorbecause it induces very high titers (1/80,000) of neutralizinganti-measles antibodies. (This is probably because it replicates in alarge number of cells of different types.) One may hope, therefore, thatthe antibody response against the engineered HIV gps will also bestrong. Furthermore, measles vaccine is also a potent inducer of longlasting cellular responses. The recombinant vaccines inducedcross-neutralizing antibodies as well as cellular immune responses aftera single injection in CD46^(+/−) IFN-α/β_R^(−/−) mice. Furthermore, theyinduced immune responses against HIV in mice and macaques with apre-existing anti-MV immunity.

Construction of Mutant HIV-1 Envelope Glycoproteins

The envelope glycoproteins used in this study (FIG. 1) were derived fromSHIV89.6P, a chimeric simian/human immunodeficiency virus which containstat, rev, vpu and env genes of HIV1 in an SIVmac239 background (Reimann,K. A., et al 1996. A chimeric simian/human immunodeficiency virusexpressing a primary patient human immunodeficiency virus type 1 isolateenv causes an AIDS-like disease after in vivo passage in rhesus monkeys.J Virol. 70:6922-6928). The env gene is derived from a cytopathicprimary HIV1 isolate, 89.6, which is tropic for both macrophages and Tcells (Collman, R., et al 1992. An infectious molecular clone of anunusual macrophage-tropic and highly cytopathic strain of humanimmunodeficiency virus type 1. J Virol. 66:7517-7521). The env sequencewas amplified from the plasmid pSHIV-KB9 (NIH) that was previouslycloned after in vivo passages of the original virus (Karlsson, G. B., etal 1997. Characterization of molecularly cloned simian-humanimmunodeficiency viruses causing rapid CD4+ lymphocyte depletion inrhesus monkeys. J Virol. 71:4218-4225). The full-length env (gp160) wasamplified by PCR (Pfu polymerase) using primers that contain uniqueBsiWI and BssHII sites for subsequent cloning in measles vector: 160E5(5′-TATCGTACGATGAGAGTGAAGGAGAAATAT-3′; SEQ ID NO: 1) and 160E3(5′ATAGCGCGCATCACAAGAGAGTGAGCTCAA-3′; SEQ ID NO: 2). The env sequencecorresponding to the secreted form (gp140) was amplified using primers160E5 and 140E3 (5′-TATGCGCGCTTATCTTATATACCACAGCCAGT-3′; SEQ ID NO: 3).A start and a stop codon were added at both ends of the genes as well asseveral nucleotides after the stop codon in order to respect the “ruleof six”, stipulating that the number of nucleotides of MV genome must bea multiple of 6 (Calain, P., and L. Roux. 1993. The rule of six, a basicfeature for efficient replication of Sendai virus defective interferingRNA. J Virol. 67:4822-4830; Schneider, H., et al 1997. Recombinantmeasles viruses defective for RNA editing and V protein synthesis areviable in cultured cells. Virology. 227:314-322). Both gp160 and gp140env fragments were cloned in PCR®2.1-TOPO® plasmid (Invitrogen) andsequenced to check that no mutations were introduced.

Mutants with loop-deletions were generated by PCR amplification of twooverlapping fragments flanking the sequence to be deleted and annealingof these fragments by PCR. To replace the V3 sequence by the AAELDKWASAA(SEQ ID NO: 8) sequence containing the gp41 epitope (Muster, T., F. etal 1993. A conserved neutralizing epitope on gp41 of humanimmunodeficiency virus type 1. J Virol. 67:6642-6647), four primers weredesigned on both sides of BbsI and MfeI sites encompassing the V3sequence:

ΔV3A1 (SEQ ID NO: 4) (5′-ATAAGACATTCAATGGATCAGGAC-3′), ΔV3A2(SEQ ID NO: 5) (5′TGCCCATTTATCCAATTCTGCAGCATTG TTGTTGGGTCTTGTACAATT-3′),ΔV3B1  (SEQ ID NO: 6) (5′-GATAAATGGGCAAGTGCTGCAAGACAAGCACATTGTAACATTGT-3′), and ΔV3B2 (SEQ ID NO: 7)(5′-CTACTCCTATTGGTTCAATTCTTA-3′)The underlined sequences in ΔV3A2 and ΔV3B1 correspond to theAAELDKWASAA (SEQ ID NO: 8) epitope with a 12 nucleotides overlap. PCRamplifications with primer pairs ΔV3A1/ΔV3A2 and ΔV3B1/ΔV3B2 producedtwo fragments of 218 and 499 bp respectively. After gel purification,these fragments were annealed together by 15 PCR cycles without primersand amplified with ΔV3A1/ΔV3B2 primers. The resulting 705 bp fragmentwas cloned in PCR®2.1-TOPO® plasmid and sequenced. After digestion byBbsI and MfeI, the fragment lacking the sequence encoding the V3 loop(ΔV3-AAELDKWASAA; SEQ ID NO: 8)) was purified and introduced in place ofthe corresponding fragment in the gp160 and gp140 in PCR®2.1-TOPO®plasmids.

The resulting plasmids were designated pMV2-gp160ΔV3 and pMV2-gp140ΔV3.

The ΔV1V2 mutants were produced using the same procedure. Two fragmentswere amplified on both sides of V1V2 loop using the following primers:

160E5 (5′-TATCGTACG ATGAGAGTGAAGGAGAAATAT-3′; SEQ ID NO: 1), ΔV1V2A1(5′-ATTTAAAGTAACACAGAGTGGGGTTAATTT-3′; SEQ ID NO: 9), ΔV1V2B1(5′-GTTACTTTAAATTGTAACACCTCAGTC ATTACACAGGCCTGT-3′; SEQ ID NO: 10),ΔV1V2B2 (5′-TTGCATAAAATGCTCTCCCTGGTCCTATAG-3′; SEQ ID NO: 11)The italicized sequences in ΔV1V2A1 and ΔV1V2B1 correspond to a 12nucleotide overlap generated between the two fragments. PCRamplifications with primer pairs 160E5/ΔV1V2A1 and ΔV1V2B1/ΔV1V2B2produced two fragments of 400 and 366 bp respectively. After gelpurification, these fragments were annealed together by 15 PCR cycleswithout primers and amplified with 160E5/ΔV1V2B2 primers. The resulting766 bp fragment was cloned in PCR®2.1-TOPO® plasmid and sequenced. Afterdigestion with BsiWI (in 160E5 primer) and BbsI, the fragment lackingthe sequence encoding the V1V2 loop was purified and introduced in placeof the corresponding fragment in the gp160 and gp140 in PCR®2.1-TOPO®plasmids.

To obtain the ΔV1V2V3 mutants, the BsiWI/BbsI fragment lacking thesequence encoding the V1V2 loop was introduced in place of thecorresponding fragment in the PCR®2.1-TOPO®-gp140ΔV3 andPCR®2.1-TOPO®-gp160ΔV3 plasmids.

After BsiWI/BssHII digestion of the different PCR®2.1-TOPO® plasmids,the native and mutant gp160 and gp140 sequences were cloned in theEdB-tag vector in ATU position 2 and ATU position 3 (FIG. 2B). Theresulting plasmids were designated pMV2-gp160_(HIV), pMV2-gp140_(HIV).

Cells were maintained in Dubelbecco's modified Eagle's medium (DMEM)supplemented with 5% fetal calf serum (FCS) for Vero cells (Africangreen monkey kidney), or with 10% FCS, 1 mg/ml G418 for helper 293-3-46cells (35) and for P4-CCR5 cells (Hela-CD4-CXCR4-CCR5-HIVLTR-LacZ) (12).

Recovery of Recombinant MV_(EdB)-Env_(HIV89.6) Virus.

To recover the recombinant MV_(EdB)-HIV viruses from the plasmids, thedifferent EdB-HIV Env plasmids were used to transfect 293-3-46 helpercells.

To recover the measles virus from the EdB-HIV-Envplasmids cDNA, we usedthe helper-cell-based rescue system described by Radecke et al.(Radecke, F., et al 1995. Rescue of measles viruses from cloned DNA.EMBO Journal. 14:5773-5784) and modified by Parks et al. (Parks, C. L.,et al 1999. Enhanced measles virus cDNA rescue and gene expression afterheat shock. J Virol. 73:3560-3566). Human helper cells stably expressingT7 RNA polymerase and measles N and P proteins (293-3-46 cells,disclosed by Radecke et al) were co-transfected using the calciumphosphate procedure with the EdB-HIV-Env plasmids (5 μg) and a plasmidexpressing the MV polymerase L gene (pEMC-La, 20 ng, disclosed byRadecke et al). The virus was rescued after cocultivation of transfected293-3-46 helper cells at 37° C. with primate Vero cells (african greenmonkey kidney). In this case, syncytia appeared systematically in alltransfections after 2 days of coculture.

In a further experiment (FIGS. 3C-D), after overnight incubation at 37°C., the cells were heat shocked at 43° C. for 3 hours in fresh medium(40). Heat-shocked cells were incubated at 37° C. for 2 days, thentransferred onto a 70% confluent Vero cells layer (10 cm Petri dishes).Syncytia appeared in Vero cells after 2-5 days of coculture. Singlesyncytia were harvested and transferred to Vero cells grown in 35 mmwells. The infected cells were expanded in 75 and 150 cm3 flasks. Whensyncytia reached 80-90% confluence, the cells were scraped in a smallvolume of OptiMEM (Gibco BRL) and frozen and thawed once. Aftercentrifugation, the supernatant, which contained virus, was stored at−80° C.

Expression of HIV1 Glycoproteins by Recombinant MV.

The rescued recombinant viruses MV2-gp140, MV2-gp160, MV3-gp140ΔV3 andMV2-gp160ΔV3 were propagated on Vero cells and the expression of HIV Envglycoproteins was analyzed by western blotting and immunofluorescence.Infection of Vero cells by recombinant MV2 viruses (with transgeneinsertion in position 2) showed a high expression of the HIV Env gp160and gp140. The cleaved recombinant Env protein (gp120) was alsodetected. The MV3 virus (with transgene insertion in position 3)expressed lower levels of transgene, as expected due to thetranscription gradient observed in MV expression. Taken together, theseresults indicate that HIV1 Env glycoprotein and ΔV3 mutant areefficiently expressed by the recombinant MVs.

Virus titration. The titers of recombinant MV were determined by anendpoint limit dilution assay on Vero cells. 50% tissue cultureinfectious dose (TCID₅₀) were calculated using the Kärber method.

Growth Capacity of the MV_(EdB)-Env_(HIV89.6) Recombinant Viruses.

To analyze the growth capacity of MV_(EdB)-Env_(HIV89.6) viruses, Verocells were infected at different MOI (0.01 and 0.0001), incubated at 37°C., and collected at different time points. Titers of cell-associatedviruses were determined for each sample using the TCID₅₀ method on Verocells. FIG. 4 shows that using MOI of 0.0001, the growth kinetics ofMV_(EdB)-Env_(HIV89.6) viruses was delayed, as compared to standardMV_(EdB-tag). However, using an MOI of 0.01 the production ofrecombinant viruses was comparable to that of standard virus, and peaktiters of 10⁷ TCID₅₀/ml or even more were easily obtained.

In particular, monolayers of Vero cells (T-25 flasks) were infected atan MOI of 0.05 with the recombinant viruses. When syncytia reached80-90% confluence, cells were lysed in 150 mM NaCl, 50 mM Tris pH=8, 1%NP40, 0.5 mM PMSF and 0.2 mg/ml Pefabloc (Interbiotech, France).Chromatin was removed by centrifugation and the concentration of proteinin the supernatant was determined with a Bradford assay. Proteins (50μg) were fractionated by sodium dodecyl sulfate polyacrylamide gelelectrophoresis (SDS-PAGE) and transferred to cellulose membranes(Amersham Pharmacia Biotech). The blots were probed with a mousemonoclonal anti-HIV gp120 antibody (Chessie 13-39.1, NIH-AIDS Research &Reference Reagent Program) or with a monoclonal anti-MV N antibody(Chemicon, Temecula, USA). A goat anti-mouse IgG antibody-horseradishperoxidase (HRP) conjugate (Amersham) was used as second antibody.Peroxidase activity was visualized with an enhanced chemiluminescencedetection Kit (Pierce).

Mice Immunizations

Mice susceptible for MV infection were obtained as described previously(21). Transgenic FVB mice heterozygous for CD46 (32), the receptor forMV vaccine strains (24) were crossed with 129sv IFN-α/βR^(−/−) micelacking the type I interferon receptor (22). The F1 progeny was screenedby PCR and the CD46^(+/−) animals were crossed again with 129svIFN-α/βR^(−/−) mice. IFN-α/βR^(−/−) CD46^(+/−) animals were selected andused for immunization experiments. The same type of mice have alreadybeen shown to be susceptible to MV infection (20, 21).

Six-weeks-old female CD46^(+/−) IFN-α/βR^(−/−) mice were inoculatedintraperitoneally with 10⁷ TCID₅₀ of MV2-gp140, MV2-gp160, MV3-gp140ΔV3or MV2-gp160ΔV3 recombinant viruses prepared and titrated as describedabove. Mice were euthanized 7 days and 1 month post-infection. Spleensand whole blood were collected. Splenocytes were extracted from spleensand kept frozen in liquid nitrogen until use. Serums were decanted andserology was analyzed by ELISA for MV (Trinity Biotech, USA) and HIV(Sanofi Diagnostics, France).

Monkey Immunization

Two colony-bred rhesus macaques (Macaca mulatto) (seronegative forsimian type D retrovirus, simian T-cell lymphotropic virus, simianimmunodeficiency virus and MV) were vaccinated subcutaneously with 104TCID50 of MV vaccine (Rouvax, Aventis Pasteur, France). They wereboosted one year later by two injections of 5 106 TCID50 of MV2-gp140recombinant virus done at 1 month interval. Blood samples were collectedat different time points and anti-MV and anti-HIV antibodies were lookedfor.

Humoral Immune Response to Rescued Recombinant Viruses.

1^(st) Experiment

Humoral immune responses against MV and HIV Env were analyzed by ELISAin serums collected 1 month after immunization of mice. Titers weredetermined by limiting dilutions. The results presented in FIG. 5 showthat all the vaccinated mice responded to measles with high titers ofantibodies (1/50000 to 1/80000) and to HIV Env with titers between1/1000 and 1/5000 depending on the inserted sequence. The antibodytiters between MV and HIV cannot be compared because the ELISA used havenot the same sensitivity. The MV ELISA (Trinity Biotech, USA) detectedthe whole response against all MV proteins, while the HIV ELISA (SanofiDiagnostics) detected only the anti-HIV Env antibodies. The capacity ofthese sera to neutralize a primary HIV clade B isolate was tested usingindicator cells, P4R5, that express beta-galactosidase when infectedwith HIV (HeLa-CD4-CXCR4-CCR5-HIV LTR-LacZ cells). In preliminaryexperiments, we tested sera of mice immunized with recombinant MV-HIVviruses expressing native envelope glycoproteins (MV-gp160_(HIV-1) orMV_(EdB)-gp140_(HIV89.6)). The results showed that these sera had a70-50% neutralizing activity against a primary isolate, Bx08, when usedat a 1/20 dilution (FIG. 6). The neutralizing activity of sera raisedagainst the genetically engineered Env molecules is currently understudy.

2^(nd) Experiment

In another experiment (FIG. 5C-F), sera were collected one month afterimmunization and heat inactivated. Anti-MV (Trinity Biotech, USA) andanti-HIV Env (Sanofi Diagnostic Pasteur, Biorad, France) antibodies weredetected using commercial ELISA kits. An anti-mouse antibody-HRPconjugate (Amersham) was used as the secondary antibody. Titers weredetermined by limiting dilutions and calculated as the highest dilutionof serum giving twice the absorbence of a 1/100 dilution of a mixture ofcontrol sera. The same ELISA kits were used for sera from macaquemonkeys. An anti-monkey IgG secondary antibody was used to detectanti-HIV antibodies. Anti-MV antibodies were detected with an anti-humanIgG in order to be able to calibrate the assay with standards suppliedin the MV ELISA kit. They were expressed in mIU/ml. A mixture of 5samples from negative monkeys was used as the negative control. Thetiter of anti-ELDKWAS (Residues 3-9 of SEQ ID NO: 8) antibodies wasdetermined by ELISA using 96-well NeutrAvidin plates (Pierce) coatedwith the ELDKWAS (Residues 3-9 of SEQ ID NO: 8) biotynilated peptide(Neosystem, 5 μg/ml in NaHCO₃ 2 M, Na₂CO₃.H₂O 2M, pH 9.6). Sera frommice immunized with standard MV were used as negative controls.Peptide-bound antibodies were detected with anti-mouse antibody-HRPconjugate.

HIV-1 neutralization assays. Sero-neutralization was tested againstSHIV89.6p (A. M. Aubertin, Université Louis Pasteur, Strasbourg, H.Fleury, Bordeaux, France), 92US660, 92US714, 92HT593 (NIH-AIDS Research& Reference Reagent Program), and a clade A primary isolate:3253 (G.Pancino, Institut Pasteur, Paris). These viruses were propagated onPHA-stimulated human PBMC as already described (42). HIV-1neutralization assays were performed using the P4-CCR5 indicator cellline (43). P4-CCR5 cells were seeded in 96-well plates (20 000 cells perwell) and incubated at 37° C. in DMEM, 10% FCS for 24 h. The medium wasreplaced by 100 μl DMEM, 10% FCS, DEAE dextran (100 μg/ml) and the cellswere incubated at 37° C. for 30 minutes. Virus (0.5 it 1 ng p24) wasincubated with serum dilutions in 50 μl PBS at 37° C. for 20 minutes andthe virus-serum mixtures were added to the cells in triplicate. After 48hours of incubation, the β-galactosidase activity was measured using aChemiluminescence Reporter Gene Assay (Roche, USA).

Cellular Immune Responses to Rescued Recombinant Viruses.

The capacity of splenocytes from vaccinated mice to secrete α-IFN uponin vitro stimulation was tested by flow-cytometry and ELISpot assays.Frozen cells from immunized mice were thawed 18 h before functionalassays and incubated in RPMI medium supplemented with 10% 56° C.-heatedFCS (Gibco) and 10 U rh-IL2 (Boehringer Mannheim). Cell viability wasevaluated by trypan-blue exclusion.

To perform γ-IFN ELISpot assay, multiscreen-HA 96-wells plates werecoated with capture anti-mouse γ-IFN (R4-6A2, Pharmingen) in PBSsolution (6 μg/ml). After overnight incubation at 4° C., wells werewashed 4 times with PBS. The remaining protein binding sites wereblocked by incubating wells with 100 μl RPMI/FCS 10% for 1 h at 37° C.Medium was withdrawn just before addition of cell suspensions (100 μl)and stimulating agents (100 μl). Splenocytes from immunized mice wereplated at 5.10⁵ cell per well in duplicate in RPMI. Concanavalin A (5μg/ml, Sigma) was used as a positive control, and RPMI/IL2 (10 U/ml) asa negative control. Cells were stimulated either with 1 μg/ml HIV1gp120, 1 μg/ml Bovine Serum Albumin (Sigma), or Edm-Tag virus (MOI=1).After incubation for 2 h at 37° C. for viral adsorption, heated-FCS (10μl) was added in each well (10% final concentration) and plates wereincubated for 24-36 h at 37° C. To remove cells, the plates were washedtwice with PBS, 4 times with PBS containing 0.05% TWEEN™ 20 (Sigma), and2 times again with PBS. For detection, a biotinylated anti-mouse γ-IFNantibody (XMG1.2, Pharmingen) was added to each well (100 μl, 4 μg/ml inPBS-0.1% FCS). After incubation for 2 h at room temperature, plates werewashed 4 times with PBS-0.1% TWEEN™ 20 and twice with PBS.Streptravidin-Alkaline Phosphatase (AP) conjugate (Roche) (100 μl,1/2000 dilution in PBS) was added and incubated for 1-2 hours at roomtemperature. The enzyme was removed by 4 washes with PBS-0.1% TWEEN™ 20and 2 washes with PBS. Spots were then developed with BCIP/NBT colorsubstrate (Promega) prepared in AP buffer pH 9.5 (1 M Tris, 1.5 M NaCl,0.05 M MgCl2). Wells were monitored for spot formation by eye: after a15-30 minutes incubation the reaction was stopped by washing underrunning tap water. After drying at least overnight at room temperature,colored spots were counted using an automated image analysis systemELISpot Reader (Bio-Sys).

For Flow-cytometry assays, 5 10⁵ splenocytes (diluted in 100 μl RPMI)were stimulated in V-bottomed 96-wells plates with either 1 μg/ml HIV1gp120 protein (AbCys) in RPMI/IL2 (10 U/ml), or EdB-tag virus (MOI=1)diluted in 100 μl RPMI/IL2. Non stimulated control cells were incubatedwith RPMI/IL2 (10 U/ml). After incubation for 2 h at 37° C. for viraladsorption, 10 μl FCS were added in each well (10% final concentration)and plates were incubated overnight at 37° C. The medium was thenreplaced by 150 μl RPMI-10% FCS containing 10 U rh-IL2 and 10 μg/mlBrefeldin A (Sigma). Cells were incubated for 4 hours at 37° C.,harvested, stained with anti-mouse CD8-APC (Pharmingen) and anti-mouseCD4-CyCr (Pharmingen) for 20 minutes at room temperature, washed withPBS-BSA (0.5%), then fixed for 5 minutes at 37° C. in CytoFix(Pharmingen). After washing cells were resuspended in 100 μl PBS-BSA(0.5%) containing 0.1% Saponin (Sigma) and incubated for 30 minutes atroom temperature with anti-mouse γ-IFN-PE (Pharmingen). Cells werewashed again and samples were analyzed using a FACSCalibur cytometer(Becton Dickinson). The data were analyzed using Cell Quest software.

Recombinant MV Express HIV89.6 Env Glycoproteins and ReplicateEfficiently.

The anchored (gp160) and soluble (gp140) forms of the HIV Envglycoprotein (strain SHIV89.6p), with or without deletion of the V3 loopand insertion of an additional ELDKWAS (Residues 3-9 of SEQ ID NO: 8)epitope, were inserted into one of the ATU of the p(+)MV vector (FIG.2). Recombinant viruses MV2-gp140, MV2-gp160, MV3-gp140ΔV3 andMV2-gp160ΔV3 were obtained after transfection of the plasmids into the293-3-46 helper cell line and propagation in Vero cells. MV2- and MV3-refers to the site of the insertion, position 2 or 3 respectively, ofthe EnvHIV89.6 construction. Expression of the EnvHIV89.6 protein wasanalyzed by western blotting of infected-cells lysates (FIG. 3) andimmunofluorescence (not shown). The MV2-gp140 and MV2-gp160 virusesshowed a high level of expression of the EnvHIV89.6 protein (FIG. 3C,lanes 1, 2, 4). As expected, the MV2-gp160A viruses expressed the envgp160 precursor as well as the cleaved gp120 protein (FIG. 3C, lanes 2,4). In contrast, the MV2-gp140 and MV3-gp140ΔV3 viruses expressed onlythe secreted, uncleaved gp140 form. The MV3-gp140ΔV3 virus expressedslightly lower levels of transgene than viruses of the MV2-series, asexpected, due to the transcription gradient observed in MV expression(FIG. 3C, lane 3). Taken together, these results indicate thatEnv_(HIV89.6) and the ΔV3 mutants were efficiently expressed andcorrectly matured. The recombinant MV were passaged 5 times on Verocells and the expression of the transgene was compared to that of the MVnucleoprotein. FIG. 3 shows that Env_(HIV89.6) expression was similarfor passages 2 and 5, confirming the stability of expression oftransgenes in this system.

The growth of MV-Env_(HIV89.6) recombinant viruses was analyzed on Verocells using an MOI of 0.0001 or 0.01. The growth of recombinant viruseswas only slightly delayed compared to that of standard EdB-tag MVrescued from p+(MV). Viruses expressing the secreted gp140 were lessaffected than viruses expressing the anchored gp160. The gp140ΔV3recombinant grew at the same rate as control MV. The delay observed withviruses expressing the anchored gp160 may be due either to lowerreplication rate, because of the larger size of the transgene, or toreduced MV budding because of the insertion of gp160 at the surface ofthe infected cells. Nevertheless, the final yield of recombinant viruseswas comparable to that of control MV and peak titers of about 10⁶ to10⁷TCID50/ml were obtained routinely.

Induction of Humoral Immune Response to Recombinant MV in SusceptibleMice.

The immunogenicity of MV-Env_(HIV89.6) viruses was tested in geneticallymodified mice expressing the human CD46 MV receptor and lacking the TypeI IFN receptor. Increasing doses of MV2-gp160 virus (103-107 TCID50)were tested in 5 groups of 3 mice. Antibodies to MV and HIV Env werelooked for by ELIA in sera collected 1 month after immunization (FIG.5C). Both anti-MV and anti-HIV antibody titers increased when the doseof recombinant MV increased. Since high anti-MV titers were obtainedwhen animals were inoculated with 10⁶ to 10⁷ TCID₅₀, mice were immunizedwith 5.10⁶ TCID₅₀ in all further experiments. At this dose, anti-MVantibody titers were six fold higher than anti-HIV titers. One shouldkeep in mind that immunization was against HIV Env only, whereas all MVproteins were expressed during infection. To compare the immunogenicityof the different Env_(HIV) constructs, four groups of 6 mice wereinoculated intraperitoneally with various MV-Env_(HIV89.6) viruses(FIGS. 5B, 5E). All mice responded to MV (mean anti-MV titer: 5 10⁴) andto HIV Env (mean anti-HIV titer: 8 10³). No difference in anti-MV oranti-HIV or antiHIV titers was observed between the four constructstested. Interestingly, expression from the ATU 2 or the ATU 3 positionof the MV vector did not affect the antibody response. Because the ΔV3constructions expressed an additional ELDKWAS (Residues 3-9 of SEQ IDNO: 8) epitope, the antibody response against this gp41 epitope wasexamined separately using a specific ELISA assay (FIG. 5F). The resultsshowed that the ΔV3-ELDKWAS (Residues 3-9 of SEQ ID NO: 8) constructionsinduced higher titers of anti-ELDKWAS (Residues 3-9 of SEQ ID NO: 8)antibodies. The titer of 1/50 000 corresponds to the dilution of animmune serum capable of recognizing the antigen administered for theimmunization, in ELISA assay.

MV-Env_(HIV89.6) Viruses Induce Neutralizing Anti-HIV Antibodies.

The capacity of these sera to neutralize either homologous SHIV89.6pvirus or various heterologous primary HIV-1 isolates was tested using asingle cycle virus infectivity assay on P4-CCR5 indicator cells (43).P4-CCR5 cells express the CD4, CXCR4 and CCR5 HIV-1 receptors and havebeen stably transfected with an HIV LTR LacZ. Therefore, they aresusceptible to HIV-1 isolates and express β-galactosidase uponinfection. The sero-neutralization assay was validated using acombination of anti-HIV immunoglobulin (HIVIG) and monoclonal antibodies(2F5 and 2G12) previously shown to synergistically neutralize primaryHIV isolates (17). We also used sera from infected patients thatneutralize primary HIV isolates (17). We also used sera from infectedpatients that neutralize primary HIV primary isolates using a standardneutralization assay on human PBMCs (42). The neutralizing activity of aserum (Table 1) is expressed as the ratio of the reduction of infectionobtained with this serum over the reduction obtained with negativecontrol sera used at the same dilution (sera from HIV negativeindividuals and from infected patients neutralized clade B and A virusesequally well in this assay.

As shown in Table 1, antibodies induced in mice by the fourMV-Env_(HIV89.6) viruses neutralized the homologous SHIV89.6p at bothdilutions tested (1/30 and 1/60). No significant difference was observedbetween the sera obtained with the different Env constructs, indicatingthat the secreted and anchored from of HIV glycoprotein inducedneutralizing antibodies against homologous virus equally well whenexpressed by MV. Deleting the V3 loop, known to contain type-specificneutralizing epitopes, had no significant effect on the induction ofantibodies that neutralized the homologous virus. This suggests that thedeletion might have been compensated either by the addition of a secondELDKWAS (Residues 3-9 of SEQ ID NO: 8) gp41 neutralizing epitope, or bythe uncovering of other neutralizing epitopes.

The antibodies induced by the recombinant viruses neutralizedheterologous primary clade B isolates, except the 92HT593 isolate, aswell as a clade A virus. In each case, antibodies induced by theanchored gp160 were slightly more neutralizing than antibodies inducedby the secreted gp140, especially against the clade A 3253 virus. Theantibodies induced by the ΔV3-ELDKWAS (Residues 3-9 of SEQ ID NO: 8)Env_(HIV89.6) neutralized heterologous viruses more efficiently thanthose induced by the native envelope. This was particularly striking forthe Bx08 virus which could be neutralized up to 90% by sera from miceimmunized with MV2-gp160ΔV3 (1/30 dilution) but not by sera from miceimmunized with MV expressing the native Env_(HIV89.6). Thisneutralization was just as efficient as neutralization by positivecontrol sera. These results show that replacing the V3 loop ofEnv_(HIV89.6) by an additional ELDKWAS (Residues 3-9 of SEQ ID NO: 8)gp41 epitope and expressing the construct with a MV vector allowed theinduction of antibodies with cross-neutralizing activity against clade Aand B HIV-1 primary isolates, at least in the context of recombinant MVinfection of mice.

TABLE 1 Neutralization of HIV-1 primary heterologous isolates by serafrom MV-Env_(HIV89.6) immunized mice^(a). Positive controls Mab HumanHIV Mice Sera (1/60) Mice Sera (1/30) sera^(c) MV2 MV2 MV2 MV2 (2F5/Virus isolate MV2 Gp140 MV2 Gp160 MV2 Gp140 MV2 Gp160 2G12/ 4 33-(subtype) Gp140 ΔV3 Gp160 ΔV3 GP140 ΔV3 Gp160 ΔV3 HIV-IG 61/40) 1/30)SHIV 89.6 40 50 52 45 76 57 72 68 ND ND ND Bx08 (B) 0 31 0 40 0 76 18 9094 94 90 92 US 660 (B) 2.5 15 13 17 ND ND ND ND ND ND ND 92 US 714 (B)45 49 45 68 ND ND ND ND ND ND ND 92 HT 593 (B) 0 0 0 0 0 0 0 0 ND ND ND3253 (A) 0 0 18 30 0 10 43 49 73 54 45 ^(a)Serum was evaluated forneutralizing antibodies at two dilutions. Values are % reduction ininfection of primary HIV isolates on P4-CCR5 cells in presence of micesera (three mice per point). Determinations were made in triplicate andthe standard deviations were <10%. ^(b)Mix of HIVIG (2.5 mg/ml) and Mabs2F5 and 2G12 (25 μg/ml). ^(c)Numbers correspond to the nomemclature usedin Burrer et al.

Induction of Cellular Immune Response Against Recombinant MV

The results of these experiments performed with splenocytes from miceimmunized with MV2-gp160_(HIV) virus (FIG. 7) demonstrated that a singleimmunization with MV2-gp160_(HIV) virus was able to prime HIVEnv-specific lymphocytes in vivo. The γ-IFN-ELISpot assay is a sensitivemethod for antigen-specific cell numeration in fresh cells after in vivoimmunization. This assay was used to determine whether HIV-Env-specificγ-IFN-secreting cells could be detected after a single immunization withthe MV2-gp160_(HIV) virus. FIG. 7A shows that a significant number ofEnv-specific cells were present in 2/3 mice tested, 7 days as well as 1month after immunization. (For one mouse in each group the number ofspots was the same after BSA or gp120 stimulation). The number ofHIV-specific spots detected (up to 600/10⁶ cells) represents 15-20% ofMV-specific spots detected in the same mice (not shown), indicating thatrecombinant MV is able to efficiently immunize against the foreign geneexpressed.

To assess the phenotype of these Env-specific cells, 3-colorcytofluorometry experiments were performed on mice euthanized 7 daysafter immunization, at the theoretical peak of effector cellsproliferation. A representative result is shown on FIG. 7B. Thebackground γ-IFN production level for both CD4+ and CD8+ lymphocytes isshown on the left panel. For this animal, 0.09% of CD8+ lymphocytes(mean calculated for 3 mice: 0.31%) and 0.25% of CD4+ lymphocytes (mean:0.41%) were spontaneously producing γ-IFN. The frequencies of HIV-gp120T-cells (middle panel) in the CD8+ and CD4+ subsets were 1.76% (mean:1.69%) and 0.92% (mean: 0.76%) respectively. It's interesting to takeinto account that in the same immunized mouse the frequencies of Measlesspecific cells in CD8+ and CD4+ subsets were 7.63% (mean: 7.03%) and4.11% (mean: 3.50%) respectively. Indeed the recombinant MV2-gp160_(HIV)virus expresses 6 measles proteins plus one gp160 foreign protein. Thus,the frequencies of antigen-specific lymphocytes followed the recombinantgene proportions. As a conclusion, 3-color cytofluorometry performed 7days after MV2-gp160_(HIV) virus vaccination showed that both CD8+(FIG.7B, upper panel) and CD4+ (FIG. 7B, lower panel) lymphocytes specificfor HIV gp120 and measles virus were primed in vivo

Inducing an Anti-HIV Response in Animals with Pre-Existing Anti-MVImmunity.

We first tested the possibility of boosting the anti-HIV response by asecond injection of recombinant MV. Mice immunized with 5.10⁶ TCID₅₀ ofMV2-gp140 recombinant virus (3 mice per group) were boosted with asecond injection of the same recombinant MV one month after the firstinjection. The mean anti-MV and anti-HIV antibody titers at the time ofboosting were 5 10⁴ and 8 10³ respectively. These titers increased to,respectively 5 10⁵ and 5 10⁴ one month after boosting. Thus, anti-MV andHIV responses can be boosted 10 times by injecting the same dose ofrecombinant MV one month after the first immunization.

We then tested the ability of recombinant MV to induce anti-HIVantibodies in mice and monkeys in the presence of pre-existing anti-MVimmunity. Mice (3 mice per point) were first immunized with 10⁵ TCID₅₀of EdB-tag MV (without an HIV insert). High levels of anti-MV antibodieswere induced (FIG. 7C). The titer decreased slightly after 2 months andremained stable for the following 9 months. Mice were then inoculatedwith 5 10⁶ TCID₅₀ of MV2-gp140_(HIV89.6), and boosted with the same doseone month later. The titer of anti-MV antibodies was increased 100 timesand high titers of anti-HIV antibodies (5 10⁴) were induced. Thesetiters were similar to those obtained after immunization of naïveanimals with two injections.

The same experiment was performed with rhesus macaques (FIG. 7D). Twomacaques were immunized with a standard dose (10⁴ TCID₅₀) of MV vaccine(Rouvax, Aventis Pasteur). As for mice, high anti-MV antibody levelswere induced and remained stable during one year. Macaques were theninoculated with 5 10⁶ TCID₅₀ of MV2-gp140_(HIV89.6) twice at one monthinterval. Anti-MV titers increased 150 times after the first injectionof MV-HIV, while the second injection had no or little effect. Anti-HIVantibodies were induced by the first MV2-gp140_(HIV89.6) injectiondespite the presence of pre-existing anti-MV immunity. One month afterthe second MV2-gp140_(HIV89.6) injection, the anti-HIV antibody levelhad increased about 10 times and had reached titers similar to thoseobtained in mice. This level remained stable for the following 5 months.

The main goal of the present work was to test the immunogenicity ofattenuated MV-Env_(HIV) recombinant viruses. We showed that suchrecombinants were genetically stable, expressed the HIV Env protein athigh levels, and induced high titers of antibodies against both MV andthe HIV Env constructs in transgenic mice. The anti-HIV antibodiestiters were approximately 15-20% of those of the anti-MV antibodies.This corresponds roughly to the ratio of HIV/MV proteins expressed bythe recombinant viruses. HIV Env constructions with a deleted V3 loopand an additional ELDKWAS gp41 epitope induced twice as muchanti-ELDKWAS (Residues 3-9 of SEQ ID NO: 8) antibodies as nativeconstructions, suggesting that the native conformation of the additionalpeptide was conserved in spite of its ectopic position. A high level ofHIV-specific CD8+ and CD4+ cells was also induced. As much as 1.5-2% ofthe total CD8+ T-cells and 0.9% of the total CD4+ T-cells wereHIV-specific.

However, the most important aspect of our results is that these anti-HIVantibodies were neutralizing for the homologous SHIV89.6p virus as wellas for several heterologous clade A and clade B HIV-1 primary isolates.Interestingly, the anchored gp160 ΔV3-ELDKWAS (Residues 3-9 of SEQ IDNO: 8) construction induced antibodies that neutralized heterologousviruses more efficiently than those induced by the native envelope.Their neutralizing titers were similar to those of reference humanHIV-neutralizing sera. The broader neutralizing capacity of theseantibodies could be due either to the addition of a second ELDKWAS(Residues 3-9 of SEQ ID NO: 8) gp41 neutralizing epitope, or to theexposure of previously masked conserved neutralizing epitopes. Severalgroups have inserted the ELDKWAS (Residues 3-9 of SEQ ID NO: 8) epitopeinto various immunogenic molecules (44, 45, 46, 47). These studiesshowed that the conformational context in which the epitope is displayedis essential for the induction of neutralizing antibodies. A β-turn-likeconstraint was shown to be the most likely conformation structure of theELDKWAS (Residues 3-9 of SEQ ID NO: 8) epitope recognized by the 2F5neutralizing antibody (46). In our constructions, the insertion of theshort AAELDKWASAA (SEQ ID NO: 8) epitope in place of the V3 loop, whichis flanked by β-strands (28, 29), may have such a n-turn-likeconformation.

It has been shown, already, that deleting the hyper-variable loops ofHIV Env can enhance its immunogenicity (3, 48, 39). However, in previousstudies neutralizing antibodies were obtained only after multipleinjections of high amounts of soluble protein (23), or with a “primeboost” regimen using very large amounts of DNA and pure protein (3, 39).In contrast, we observed the same levels of neutralizing antibodies inmice injected with a single dose of MV-gp160ΔV3-ELDKWAS (Residues 3-9 ofSEQ ID NO: 8). Good immunogenicity in our system results probably fromthe fact that the HIV Env is expressed and processed by the immunesystem n the same way as proteins from the live MV vaccine, a highlypotent immunogen. One may hope that such levels of neutralizingantibodies could at least induce partial protection in vaccinatedindividuals. According to the data of others (3, 39), it might bepossible to increase the immunogenicity of M-HIV Env recombinants evenfurther by deleting the V1 and V2 loops of HIV gp120, notably to induceantibodies directed against the CD4-binding site. However, it has beenrecently reported that this receptor-binding site can escape from theimmune response by conformational and entropic masking (49).

The presence of anti-MV immunity in nearly the entire adult humanpopulation would seem to restrict the use of MV recombinants to infants,an already worthy goal in any event. However, several studies showedthat revaccinating already immunized individuals results in a boost ofanti-MV antibodies, suggesting that the attenuated live vaccinereplicated and expressed its proteins in spite of preexisting immunity(50). Under such circumstances, one might hope to be able to vaccinateadults against a foreign antigen with a MV recombinant. Indeed, ourresults demonstrate, both with mice and macaques, that high levels ofanti-HIV neutralizing antibodies can be obtained in the presence ofpre-existing anti-MV immunity.

Various “prime-boost” regimen, using combinations of naked DNA and viralvectors such a sMVA (1) or Adenovirus (29), gave reasonable protectionagainst a challenge with pathogenic SHIV89.6p. In the present study, weshow that a single injection of MV is able to combine humoral andcellular responses at levels similar to those induced by these complexcombinations.

The same recombinants have been prepared using the cloned Schwarz strainas a vector. This should raise their immunogenicity even further.

EXAMPLE II: CONSTRUCTION OF SCHWARZ MEASLES VIRUSES (MVSCHW) EXPRESSINGHIV-1 ANTIGENS

In order to test their capacity as vaccine candidates against HIVinfection, we constructed several recombinant Schwarz measles viruses(MV) expressing HIV-1 antigens. Different HIV-1 genes from differentopen reading frames were constructed and introduced in additionaltranscription units in the Schwarz MV cDNA that we previously cloned(pTM-MVSchw). After rescue of the different recombinant Schwarz measlesviruses, the expression of the different HIV-1 proteins was analyzed bywestern blotting of infected-cells lysates (FIGS. 3A-D).

Different immunogens were constructed from HIV-1 Env glycoprotein(hereafter 1-8), Gag protein (hereafter 9), and Tat protein (hereafter10):

-   -   1. Secreted glycoprotein gp140 from HIV-1 89.6p    -   2. Anchored glycoprotein gp160 from HIV-1 89.6p    -   3. Secreted glycoprotein gp140 from HIV-1 89.6p deleted from        hypervariable region V3 and additional AAELDKWASAA (SEQ ID        NO: 8) epitope (gp140HIV_(89.6) ΔV3-ELDKWAS (Residues 3-9 of SEQ        ID NO: 8))    -   4. Anchored glycoprotein gp160 from HIV-1 89.6p deleted from        hypervariable region V3 with an additional AAELDKWASAA (SEQ ID        NO: 8) epitope (gp160HIV_(89.6) ΔV3-ELDKWAS(Residues 3-9 of SEQ        ID NO: 8))    -   5. Secreted glycoprotein gp140 from HIV-1 89.6p deleted from        hypervariable regions V1-V2 (gp140HIV_(89.6)ΔV1V2)    -   6. Anchored glycoprotein gp160 from HIV-1 89.6p deleted from        hypervariable regions V1-V2 (gp160HIV_(89.6)ΔV1V2)    -   7. Secreted glycoprotein gp140 from HIV-1 89.6p deleted from        hypervariable regions V1-V2-V3 (gp140HIV_(89.6) ΔV1V2V3)    -   8. Anchored glycoprotein gp160 from HIV-1 89.6p deleted from        hypervariable regions V1-V2-V3 (gp160HIV_(89.6) ΔV1V2V3)    -   9. Gag polyprotein (p17p24, delta myr) from HIV-1 (clade B        consensus) truncated from the nucleoprotein ORF in C-terminal        (p17p24∂myrHIV-1B)    -   10. Tat protein from HIV-1 89.6p (TatHIV_(89.6))

The HIV env genes encoding the different forms of the Env protein weregenerated by PCR amplification from plasmid pSHIV-KB9 (NIH-AIDS Research& Reference Reagent Program). The specific sequences were amplifiedusing PfuTurbo DNA polymerase (Stratagene) and specific primers. Togenerate the different deletions, overlapping fragments flanking thesequences to be deleted were generated and annealed together by PCR.They were then introduced by enzyme restriction cloning in place of thecorresponding fragment in the gp160 and gp140 sequences already clonedin PCR®2.1-TOPO® plasmids (FIG. 1A). The different sequences generatedinclude a start and a stop codon at both ends and respect the “rule ofsix”, stipulating that the nucleotides number of MV genome must bedivisible by 6 (7, 8). After BsiWI/BssHII digestion, the different HIVsequences were introduced in the pTM-MVSchw vector in ATU position 2 or3 (FIG. 1B). The resulting plasmids were designated:

-   -   1. pTM-MVSchw2-gp140_(HIV)    -   2. pTM-MVSchw2-gp160_(HIV)    -   3. pTM-MVSchw2-gp140ΔV3_(HIV)    -   4. pTM-MVSchw2-gp160ΔV3_(HIV)    -   5. pTM-MVSchw2-gp140_(HIV) ΔV1V2    -   6. pTM-MVSchw2-gp160_(HIV) ΔV1V2    -   7. pTM-MVSchw2-gp140_(HIV) ΔV1V2V3    -   8. pTM-MVSchw2-gp160_(HIV) ΔV1V2V3    -   9. pTM-MVSchw2-Gag_(HIV) (p17-p24 Δmyr)    -   10. pTM-MVSchw3-Tat_(HIV)

A recombinant virus expressing both Gag and gp140 in both positions 1and 2 of the measles Schwarz vector was produced.

-   -   11. pTM-MVSchw2-Gag_(SIV239) (p17-p24 Δmyr)-3-gp140_(HIV)

This virus expressed both proteins (Fig z). Such constructs allow theproduction of HIV, SHIV or SIV assembled Gag-Env “virus like particles”in cells infected by recombinant measles virus.

The HIV-1 immunogenic sequences represented in FIG. 16 have beengenerated:

EXAMPLE III: RECOMBINANT MEASLES VIRUSES EXPRESSING DIFFERENT VIRALTRANSGENES

In order to demonstrate the immunizing and protective capacities of MVas a pediatric vaccination vector, a series of recombinant measlesviruses expressing different viral transgenes (listed below) from otherviruses were constructed and studied. The results presented here wereobtained with the old EdB-tag vector. However, we have shown that theEdB-tag was 100 times less immunogenic than the Schwarz vaccine. ThusMV_(EdB) recombinant viruses were inoculated at higher doses. All theinserted sequences with good immunological records can be obviouslyinserted in the Schwarz vector.

Viral genes which have been already inserted in the recombinant measlesviruses:

HIV clade B 89.6P gp160 gp140 gp160ΔV3 gp140ΔV3 gp160ΔV1V2 gp140ΔV1V2gp160ΔV1V2V3 gp140ΔV1V2V3 tat

HIV clade B consensus codon optimized Gag (p17-p24)

SIV Mac 239 Nef NefΔMyr Nef29-236 Tat HTLV-I Env Gag (p19-p24) Tax

EXAMPLE IV: RECOMBINANT MEASLES VIRUSES EXPRESSING ENV AND NS1 FROMYELLOW FEVER VIRUS HAVE IMMUNE CAPACITY

Because a pediatric bivalent vaccine against measles and yellow fevershould be useful, we constructed recombinant MV expressing the Env andNS1 proteins from Yellow Fever Virus (YFV 17D204, Pasteur vaccinestrain) and tested their capacity to protect mice from a lethal YFVchallenge.

Construction of MV-YFV Recombinant Plasmids.

The env gene was PCR amplified with Pfu polymerase using primers thatcontain unique BsiWI and BssHII sites for subsequent cloning in MVvector: MV-YFVEnv5 (5′-TATCGTACGATGCGAGTCGTGATTGCCCTACTG-3′; SEQ ID NO:12) and MV-YFVEnv3 (5′-ATAGCGCGCTTATGTGTTGATGCCAACCCA-3′; SEQ ID NO:13). The Env protein thus generated (amino acids 270-753 in YFVpolyprotein) contained the signal peptide in N-terminal and a part ofthe tramsmenbrane region in C-terminal. The NS1 sequence was PCRamplified in the same way with Pfu polymerase using primers: MVYFVNS5(5′-TATCGTACGATGAGAAACA TGACAATGTCC-3′; SEQ ID NO: 14) and MVYFVNS3(5′-ATAGCGCGCTTAATGGCTTTCATGCGTTT TCC-3′; SEQ ID NO: 15). The NS1protein (amino acids 754-1122 in YFV polyprotein) contained its signalpeptide sequence. A start and a stop codon were added at both ends ofthe genes as well as several nucleotides after the stop codon in orderto respect the “rule of six”, stipulating that the nucleotides number ofMV genome must be a multiple of 6 (7). Both env and NS1 fragments werecloned in PCR®2.1-TOPO® plasmid (Invitrogen) and sequenced to check thatno mutations had been introduced. After BsiWI/BssHII digestion of thePCR®2.1-TOPO® plasmids, the env and NS1 sequences were cloned in theEdB-tag vector in ATU position 2 giving plasmids: EdB-Env_(YFV) andEdB-NS1_(YFV).

Recovery of Recombinant EdB-Env_(YFV) and EdB-NS1_(YFV) Viruses.

EdB-Env_(YFV) and EdB-NS1_(YFV) plasmids were used to transfect 293-3-46helper cells as described above, and recombinant viruses were rescuedfrom transfected cells cocultivated with Vero cells. Recombinant viruseswere passaged two times on Vero cells and tested for transgeneexpression.

Expression of YFV Proteins by Recombinant MV.

The rescued recombinant viruses MV2-Env_(YFV) and MV2-NS1_(YFV) werepropagated on Vero cells and the expression of YFV proteins was analyzedby immunofluorescence. FIG. 9 shows that syncytia of Vero cells infectedby recombinant MV2-YFV viruses showed a high expression of the YFV Envand NS1 proteins as detected with a mouse anti-YFV polyclonal serum. Inorder to determine whether the expression of YFV genes was stable, therescued recombinant viruses were serially passaged on Vero cells. After10 passages all the syncytia observed in infected cells were positivefor YFV (not shown). Taken together, these results indicate that Env andNS1 proteins from YFV are efficiently and stably expressed over severalpassages by the recombinant MVs.

Mice Immunization with MV-YFV Recombinant Viruses.

A mixture of both MV2-Env_(YFV) and MV2-NS1_(YFV) viruses (10⁷ TCID₅₀)was inoculated intraperitoneally to six CD46^(+/−) IFN-a/bR^(−/−) miceas described above (see MV-HIV gp experiments). As a control, six othermice received the same dose of standard measles vaccine. After onemonth, mice were intracranially challenged with YFV 17D204 (10 LD₅₀determined on FVB mice). FIG. 10 shows that 65% of MV-YFV immunizedanimals were fully protected against the challenge, while all animalsvaccinated with standard MV died between 6 and 7 days post-challenge.Moreover, a 4-days delay in mortality was observed in mice immunizedwith MV-YFV, and these mice did not die with the same encephaliticclinical symptoms than mice vaccinated with standard MV vaccine. Thedisease was attenuated and consisted of limb paralysis. It has to benoticed that IFN-α/bR^(−/−) mice are much more sensitive to viralinfections than immunocompetent mice (10²-10⁴ times). For this reason,the lethal dose determined on immunocompetent mice was probably too highfor IFN-α/bR^(−/−) mice. The same experiment is underway using severaldecreasing doses of YFV challenge viruses.

In conclusion, this preliminary experiment shows that the immuneresponses induced by recombinant MV against YFV proteins are able toprotect mice against a lethal challenge.

The above constructs were made by using the sequences disclosed on FIGS.12A and 12B.

The same principles for the preparation of constructs would apply withsequences disclosed on FIGS. 12C and 12D.

EXAMPLE V: VACCINATION AGAINST WNV WITH A LIVE ATTENUATED MEASLES VIRUS(SCHWARZ STRAIN) EXPRESSING THE SECRETED FORM OF THE E GLYCOPROTEIN OFTHE WNV (WEST NILE VIRUS)

We constructed a recombinant Schwarz measles attenuated virus expressingthe WNV E soluble form and tested its capacity as vaccine candidateagainst WN encephalitis. The WN cDNA corresponding to the sE protein ofIS-98-ST1 strain of WNV was introduced in an additional transcriptionunit in the Schwarz MV cDNA (pTM-MVSchw CNCM I-2889). After rescue ofthe recombinant Schwarz measles virus, its capacity to protect mice froma lethal WNV encephalitis following intraperitoneal challenge wastested.

A) Materials and Methods

A.1 Cells and WN Virus

The IS-98-ST1 strain of WN virus was produced on Aedes AP61 mosquitocells according to the protocol described in Desprès et al (51), Mashimoet al (52) and Lucas et al (53). The Vero-NK cell clone used in thisstudy was selected for its capacity to fuse after infection with measlesvirus and to amplify the WN virus.

A.2 Titration of WN virus on AP61 mosquito cells by immunodetection offocuses viral replication (Focus Immuno Assay, FIA).

The titration was performed according to the protocol described inDesprès et al (51), Mashimo et al (52) and Lucas et al (53).

The infectious titer of WN virus on AP61 cells was determined as focusforming units on AP61 cells (AP61 UFF/ml).

A.3 Purification of WN Virus Produced on AP 61 Cells.

The purification was carried out according to the protocol described inDesprès et al (51), Mashimo et al (52) and Lucas et al (53).

Briefly, the viral particles present in supernatants of AP61 cellsinfected during 3 days with WN virus strain IS-98-ST1 (MOI 0.4) wereconcentrated in 7% PEG 6000 and then purified in 30-60% discontinuoussaccharose gradient and in 10-50% linear saccharose gradient. WN viriousin 30% saccharose were stored at −80° C. The obtained infectious titerswere about 10¹⁰ AP61 FFU/ml.

A.4 Anti-WN Antibody Detection in ELISA

The anti-WN antibody titers of diluted sera (1:100) were determined byELISA on a given quantity of 10⁶ AP₆₁ FFU of WN IS-98-ST1 virionspurified in saccharose gradient. The protocol is described in Desprès etal (1993) and Mashimo et al (2002).

A.5 Anti-WN Immune Sera

Anti-WN immune sera were collected in adult mice genetically resistantto viral encephalitis (Mashimo et al—2002) which were tested during atleast one month with intraperitoneal inoculation of 10³ AP₆₁ FFU of WNvirus strain IS-98-ST1.

The anti-WN antibody titer of 1:100 diluted immunsera were measured inELISA and were about 1.4 DO units. The neutralizing titers (TNRF90) ofanti-WN sera were about 1600.

Ascites of mice (HMAF) against WN strain IS-98-ST1 were obtained fromanimals which had been hyperimmunized with brain homogenates of babymice inoculated with WN. The ELISA titers of anti-WN HMAF, diluted to1:1000 were about 1 DO unit.

The anti-WN immune sera were used for indirect immunofluorescence andfor passive seroprotection assays against the disease. Anti-WN HMAF wereused for membrane immunodetection of viral proteins.

A6. Construction of Recombinant Schwarz Measles Virus Expressing WN sE

The WNV env gene encoding the secreted form of the protein was generatedby RT-PCR amplification of viral RNA purified from viral particles (WNVIS-98-ST1 strain). The specific sequence was amplified using PfuTurboDNA polymerase (Stratagene) and specific primers that contain uniquesites for subsequent cloning in pTM-MVSchw vector: MV-WNEnv55′-TATCGTACGATGAGAGTTGTGTTTGTCGTGCTA-3′ (SEQ ID NO: 20; BsiWI siteitalicized) and MV-WNEnv3 5′-ATAGCGCGCTTAGACAGCCTTCCCAACTGA-3′ (SEQ IDNO: 21; BssHII site italicized). A start and a stop codon were added atboth ends of the gene. The whole sequence generated is 1380 nucleotideslong, including the start and the stop codons and respects the “rule ofsix”, stipulating that the nucleotides number of MV genome must bedivisible by 6 [Calain, 1993 (7); Schneider, 1997 (28)]. The Env proteinthus generated contains its signal peptide in N-term (18 aa) and notransmembrane region. Thus, It represents amino acids 275-732 in WNVpolyprotein and has the following sequence:

(SEQ ID NO: 22) atgagagttgtgtttgtcgtgctattgcttttggtggccccagcttacagcttcaactgccttggaatgagcaacagagacttcttggaaggagtgtctggagcaacatgggtggatttggttctcgaaggcgacagctgcgtgactatcatgtctaaggacaagcctaccatcgatgtgaagatgatgaatatggaggcggtcaacctggcagaggtccgcagttattgctatttggctaccgtcagcgatctctccaccaaagctgcgtgcccgaccatgggagaagctcacaatgacaaacgtgctgacccagcttttgtgtgcagacaaggagtggtggacaggggctggggcaacggctgcggattatttggcaaaggaagcattgacacatgcgccaaatttgcctgctctaccaaggcaataggaagaaccatcttgaaagagaatatcaagtacgaagtggccatttttgtccatggaccaactactgtggagtcgcacggaaactactccacacaggttggagccactcaggcagggagattcagcatcactcctgcggcgccttcatacacactaaagcttggagaatatggagaggtgacagtggactgtgaaccacggtcagggattgacaccaatgcatactacgtgatgactgttggaacaaagacgttcttggtccatcgtgagtggttcatggacctcaacctcccttggagcagtgctggaagtactgtgtggaggaacagagagacgttaatggagtttgaggaaccacacgccacgaagcagtctgtgatagcattgggctcacaagagggagctctgcatcaagctttggctggagccattcctgtggaattttcaagcaacactgtcaagttgacgtcgggtcatttgaagtgtagagtgaagatggaaaaattgcagttgaagggaacaacctatggcgtctgttcaaaggctttcaagtttcttgggactcccgcagacacaggtcacggcactgtggtgttggaattgcagtacactggcacggatggaccttgcaaagttcctatctcgtcagtggcttcattgaacgacctaacgccagtgggcagattggtcactgtcaacccttttgtttcagtggccacggccaacgctaaggtcctgattgaattggaaccaccctttggagactcatacatagtggtgggcagaggagaacaacagatcaatcaccattggcacaagtctggaagcagcattggcaaagcctttacaaccaccctcaaaggagcgcagagactagccgctctaggagacacagcttgggactttggatcagttggaggggtgttcacctcagttggga aggctgtctaa  (SEQ ID NO: 23)MRVVFVVLLLLVAPAYSFNCLGMSNRDFLEGVSGATVVVDLVLEGDSCVTIMSKDKPTIDVKMMNMEAVNLAEVRSYCYLATVSDLSTKAACPTMGEAHNDKRADPAFVCRQGVVDRGWGNGCGLFGKGSIDTCAKFACSTKAIGRTILKENIKYEVAIFVHGPTTVESHGNYSTQVGATQAGRFSITPAAPSYTLKLGEYGEVTVDCEPRSGIDTNAYYVMTVGTKTFLVHREWFMDLNLPWSSAGSTVWRNRETLMEFEEPHATKQSVIALGSQEGALHQALAGAIPVEFSSNTVKLTSGHLKCRVKMEKLQLKGTTYGVCSKAFKFLGTPADTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANAKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTTTLKGAQRLAALGDTAW DFGSVGGVFTSVGKAV* 

After agarose gel purification, the PCR fragment was cloned inPCR®2.1-TOPO® plasmid (Invitrogen) and sequenced to check that nomutations were introduced. After BsiWI/BssHII digestion of thePCR®2.1-TOPO® plasmid, the DNA fragment was cloned in the pTM-MVSchwvector in ATU position 2 giving plasmid: pTM-MVSchw-sE_(WNV) accordingto FIG. 13.

A7. Production of Recombinant Measles Virus Expressing WN sE

To recover recombinant MV from plasmid, we used the helper-cell-basedrescue system described by Radecke et al. [Radecke, 1995 (35)] andmodified by Parks et al. [Parks, 1999 (40)]. Human helper cells stablyexpressing T7 RNA polymerase and measles N and P proteins (293-3-46cells, a kind gift from MA Billeter, University of Zurich) weretransfected using the calcium phosphate procedure withpTM-MVSchw-sE_(WNV) plasmid (5 μg) and a plasmid expressing the MVpolymerase L gene (pEMC-La, 20 ng). After overnight incubation at 37°C., the transfection medium was replaced by fresh medium and a heatshock was applied (43° C. for two hours) [Parks, 1999 (40)]. After twodays of incubation at 37° C., transfected cells were transferred on aCEF cells layer and incubated at 32° C. in order to avoid adaptation ofthe Schwarz vaccine that was originally selected on CEF cells and iscurrently grown on these cells. Infectious virus was recovered between 3and 7 days following cocultivation. The recombinant virus was alsorescued by the same technique after cocultivation of transfected293-3-46 helper cells at 37° C. with Vero cells (african green monkeykidney, clone Vero-NK). In order to increase the yield of rescue andbecause these recombinant viruses were prepared to be used be used inmice experiments, we used Vero cells as producing cells in place of theusual chick embryo fibroblasts (CEF). Single syncytia were harvested andtransferred to Vero cells grown in 35 mm wells in Dulbebecco's modifiedEagle's medium (DMEM) supplemented with 5% fetal calf serum (FCS). Theinfected cells were expanded in 75 and 150 cm3 flasks. When syncytiareached 80-90% confluence (usually 36-48 hours post infection), thecells were scraped in a small volume of OptiMEM (Gibco BRL) and frozenand thawed once. After low-speed centrifugation to pellet cellulardebris, the supernatant, which contained virus, was stored at −80° C. Wehave shown that two passages of the Schwarz virus on Vero cells did notchange its immunogenic capacities in macaques.

A8. Titration of Recombinant MV-WN Virus

The titers of recombinant MV were determined by an endpoint limitdilution assay on Vero cells. 50% tissue culture infectious dose(TCID₅₀) were calculated using the Kärber method [Karber, 1931 (41)].

A9. Immunofluorescence Detection of WNV sE Expressed in Vero CellsInfected by MV-WN sE Recombinant Virus.

The expression of the WN sE protein in cells infected by recombinantMV-WN sE was detected by immunofluorescence. Vero cells were grown onpolyornithine-coated coverslips and infected by MV-WN sE at an MOI of0.05. After two days of infection, coverslips were washed twice in PBSand fixed for 15 minutes in paraformaldehyde (4% in PBS). In some cases,cells were permeabilized by Triton X100 (0.1%, 5 min). After two PBSwashes, coverslips were incubated for 15 minutes at room temperature inPBS with 2% goat serum, then incubated for 1 hour at room temperaturewith mouse anti-WNV immune sera or mouse anti-WNV HMAF (see A5) dilutedin PBS with 2% goat serum. After washing in PBS, cells were incubatedfor 45 minutes at room temperature with R-phycoerythrin-conjugated goatanti-mouse IgG (SBA, Birmingham). Following washing in PBS, coverslipswere mounted on slides with fluoromount (Southern Biotech Associatesinc., Birmingham, Ala.).

A10. Anti-MV Antibody Detection by ELISA

Anti-MV antibodies were detected using a standard ELISA kit (TrinityBiotech, USA). An anti-mouse antibody-HRP conjugate (Amersham) was usedas the secondary antibody. Titers were determined by limiting dilutionsand calculated as the highest dilution of serum giving twice theabsorbence of a 1/100 dilution of a mixture of control sera.

A.11 Neutralization Test by Reduction of Viral Replication Focuses(TNRF90) on VERO Cells.

Successive dilutions of sera were prepared for testing in DMEM Glutamaxwith 2% decomplemented FCS (Fetal Calf Serum) in tubes of 0.5 ml.

For 0.1 ml of diluted serum in DMEM Glutamax with 2% FCS, 0.1 ml of DMEMGlutamax/2% FCS containing 100 AP61 UFF of WN virus strain IS-98-ST1 wasadded.

Control cell: 0.2 ml of DMEM 0.2% FCS

Control virus: 0.2 ml of DMEM Glutamax/2% FCS containing 100 AP61UFF ofWN virus strain IS-98-ST1.

2 hours with mild rotation at 37° C.

Plates with 12 cups with ˜150 000 VERO HK cells per cup which are grownin monolayers for 24 hours in DMEM Glutamax 5% FCS

1 washing in DMEM of cell layers.

Add 0.2 ml of DMEM Glutamax/2% SVF

Add 0.2 ml of a mixture serum/WN virus on cell layers.

Incubate 2 hours at 37° C. in CO₂.

Withdraw the serum/WN virus mixture of infected cell layers.

1 washing in DMEM of infected cell layers.

Add 1 ml of DMEM 2% SVF per cup.

Add 1 ml of CMC 1.6% diluted in DMEM Glutamax/2% SVF

Incubate 2 days at 37° C. in CO₂.

The plaques were revealed through FIA technique. The last dilution ofimmunsera which neutralize at least 90 of 100 UFF of WN virus tested onVERO cells were determined (TNRF90: Test de Neutralisation par Réductionde Foyers de replication virale à 90%). The titer of neutralizingantibodies of the sera was determined by TNRF90.

A.12 Production of WN Virus Pseudo-Particles by Cell LineMEF/3T3.Tet-Off/Pr ME.WN #h2.

Pseudo-particles of WN virus strain IS-98-ST1 composed of prME complexedglycoproteins were secreted by MEF/3T3.Tet-Off/pr ME.WN #h2 line inducedfor the expression of viral proteins (CNCM I-3018). They were purifiedfor supernatants of 3-day cell culture according to the protocol usedfor WN virus purification.

Passive seroprotection assay against WN virus in adult BALB/c mice.

6-week-old BALB/c mice were provided by the Janvier breeding Center. Thedose for viral test is 100 ap61 UFF, i.e., 10 DL 50 (Tomoshi et al 2002)diluted in 100 μl of DPBS supplemented with 0.2% BSA (Bovine SerumAlbumine) pH7.5 (Sigma) which are inoculated intraperitoneally. Theaverage time for lethal effect was 10 days. Animals were observed for 2to 3 weeks.

The sera to be tested for passive seroprotection in mice are diluted in0.1% DPBS/0.2% BSA and inoculated 24 hours prior to viral test.

B) Results and Conclusions

B1. Production of Recombinant Measles Virus Expressing WN sE

cDNA encoding E protein of WNV strain IS-98-ST1 deleted for itstransmembrane anchoring region was inserted in the genome of measlesvirus (Schwarz strain) according to FIG. 13.

B.2. Preliminary Assays of Passive Seroprotection Against WN Virus inMice

Anti-WN immune sera to be tested were obtained from mice geneticallyresistant to the disease (52). The anti-WN sera, late taken, wereinjected at dilutions 1:10 (16 TNRF₉₀) et 1:40 (4 TNRF₉₀) in a finalvolume of 0. 1 ml DPBS/0.2% SAB intraperitoneally in adult BALB/c micegenetically sensitive. The antibodies were administered only 24 hoursprior to the viral test or 24 hours before and 24 hours after the testwith 10 DL₅₀ of strain IS-98-ST1 of WN virus. The negative control wasthe injection of normal serum of mice at 1:10. The neurovirulence of WNvirus was evaluated in mice tested with DPBS/0.2% SAB. The results ofpassive protection after two weeks of viral tests were as follows:

TABLE 1 Passive seroprotection against WNV encephalitis in adult BALB/cmice. Passive transfer Mortality MDOD* PBS/BSA (0.2%) 6\6 10.5 (±1.5)normal serum (1:10) 6\6 12.5 (±1.5) anti-WNV serum (1:10), 2 doses** 0\6NA anti-WNV serum (1:40), 2 doses 0\6 NA anti-WNV serum (1:10), 1dose*** 1\6 12 anti-WNV serum (1:40), 1 dose 0\6 NA (*Mean Day Of Death± SD) (**Day −1 and Day +1 of virus challenge) (***Day −1 of viruschallenge)

To conclude, a unique injection of anti-WN antibodies (2.5 à 10 μl ofserum) obtained from mice genetically resistant to WN virus, saidinjection being carried out intraperitoneally in adult mice sensitive toviral encephalitis provides passive protection against a test dose.

It is noted that the sera of BALB/c mice having received anti-WNprotective antibodies and resisting to viral infection have anti-WNantibody titers by ELISA which are of about 1 DO unit (for a dilution ofserum of 1:100) after one month of test. This indicates that the WNvirus inoculated for the test has achieved replication in protectedmice, inducing a humoral response. If passive seroprotection protectsagainst lethal encephalitis due to WN virus, it does not seem to beappropriate in order to prevent viral propagration in infectedindividual.

B.3. Vaccination of CD46^(+/−) IFN-α/βR^(−/−) Mice with MV/WN sE Virus

Mice susceptible for MV infection were obtained as described previously[Mrkic, 1998 (21)]. FVB mice heterozygous for the CD46 MV receptortransgene [Yannoutsos, 1996 (32)] were crossed with 129Sv IFN-α/βR^(−/−)mice [Muller, 1994 (22)]. The F1 progeny was screened by PCR and theCD46^(+/−) animals were crossed again with 129v IFN-α/βR^(−/−) mice.IFN-α/βR^(−/−) CD46^(+/−) animals were selected and used forimmunization experiments. Six-week-old CD46^(+/−) IFN-α/βR^(−/−) micewere inoculated intraperitoneally with a single dose of standard MVvaccine (10⁶ TCID₅₀, 3 mice) or MV-WN sE recombinant virus (10⁴ or 10⁶TCID₅₀, 6 mice per dose) in 300 μl phosphate buffer saline (PBS).

A serum has been taken from eye after one month of vaccination with aunique dose in order to determine the production of anti-MV, anti-WN Eand neutralizing antibodies against the test virus.

b) Sera Diluted to 1:100 and Tested for Antibodies by ELISA on PurifiedNV Virion, for:

-   -   DO unit    -   Ascite of anti-WN mice: 1 (control+)    -   Serum of anti-WN mice: 0.8 (control+)    -   Serum of MV vaccinated mice: 0.110±0.005    -   Serum of MV/WN sE vaccinated mice, 10⁴ DCIP₅₀: 0.635±0.040        (males)    -   Serum of MV/WN sE vaccinated mice, 10⁴ DCIP₅₀: 0.815±0.005        (females)    -   Serum of MV/WN sE vaccinated mice, 10⁶ DCIP₅₀: 0.800±0.200        (males)    -   Serum of MV/WN sE vaccinated mice, 10⁶ DCIP₅₀: 0.900±0.195        (females)

c) In Vitro Seroneutralization Test for WNV on VERO Cells.

TNRF₉₀ of pools of sera on 100 AP ₆₁UFF of strain IS-98-ST1 of WN virusin VERO cells:

-   -   TNRF₉₀    -   Serum of MV vaccinated mice: <10    -   Serum of MV vaccinated mice MV-WN sE, 10⁴ DCIP₅₀: 400    -   Serum of MV vaccinated mice MV-WN sE, 10⁶ DCIP₅₀: 800

To conclude, antibodies directed against soluble E glycoprotein WN virushave the capacity to neutralize strain IS-98-ST1 used for the test by WNvirus in mice in vitro.

A vaccine boost in immunized CD46^(+/−)IFN-α/βR^(−/−) mice has beencarried out 1 month after the beginning of vaccination with a uniquedose, identical to the dose of the first injection.

After 2 weeks of boosting, sera were tested by ELISA and in TNRF₉₀ asabove:

a) Sera Diluted to 1:100 and Tested for Antibodies by ELISA on PurifiedWN Virion:

-   -   DO Unit    -   Ascite of anti-WN mice: 1.4 (control+)    -   Serum of anti-WN mice: 1 (control+)    -   Serum of MV vaccinated mice: 0.110±0.005    -   Serum of MV-WN sE vaccinated mice, 10⁴ DCIP₅₀: 0.810±0.100        (males)    -   Serum of MV-WN sE vaccinated mice, 10⁴ DCIP₅₀: 1.150±0.015        (females)    -   Serum of MV-WN sE vaccinated mice, 10⁶ DCIP₅₀: 0.965±0.230        (males)    -   Serum of MV-WN sE vaccinated mice, 10⁶ DCIP₅₀: 1.075±0.240        (females)

b) Seroneutralization Test In Vitro on VERO Cells

TNRF₉₀ of pools of sera on 100 AP ₆₁UFF of strain IS-98-ST1 of WN virusin VERO cells:

-   -   TNRF₉₀    -   Serum of boosted MV mice: <10    -   Serum of boosted MV-WN sE, 10⁴ DCIP₅₀ mice: >1600    -   Serum of boosted MV-WN sE, 10⁶ DCIP₅₀ mice: >1600

After 4 weeks of boosting, the sera were tested by ELISA and in TNRF₉₀as above:

a) Sera diluted at 1:100 and tested for antibodies by ELISA on purifiedWN virion:

-   -   DO unit    -   Ascite of anti-WN mice: 1.7 (control+)    -   Serum of anti-WN mice: 1.2 (control+)    -   Serum of MV vaccinated mice: 0.2    -   Serum of MV-WN sE vaccinated mice, 10⁴ DCIP₅₀: 1.52 (±0.15)    -   Serum of MV-WN sE vaccinated mice, 10⁶ DCIP₅₀: 1.76 (±0.10)

b) Seroneutralization In Vitro on VERO Cells

TNRF₉₀ of pools of sera on 100 AP ₆₁UFF of strain IS-98-ST1 of WN viruson VERO cells:

-   -   TNRF₉₀    -   Serum of MV-WN sE vaccinated mice, 10⁴ DCIP₅₀: 4000 (males)    -   Serum of MV-WN sE vaccinated mice, 10⁴ DCIP₅₀: 8000 (females)    -   Serum of MV-WN sE vaccinated mice, 10⁶ DCIP₅₀: 10 000-12 000

To conclude, after a boost with a unique dose, the anti-WNV antibodytiters and the anti-WNV neutralizing antibody titers were significantlyincreased by a 10-fold factor or more.

Splenocytes of CD46^(+/−) IFN-α/βR^(−/−) mice immunized with twoinjections separated by 4 weeks with the MV-WN sE virus with doses of10⁴ or 10⁶ DCIP₅₀ are tested in ELISpot and flux/cytometry for the T CD4and CD8 response after in vitro stimulation with purified viralpseudo-particules in saccharose gradients starting from supernatants ofinduced MEF/3T3.Tet-Off/prME.WN #h-2 (CNCM I-3018) cell line.

B.4. Passive Anti-WN Seroprotection Test in BALB/c with Anti-EAntibodies

Immune sera of CD46^(+/−) IFN-α/βR^(−/−) mice vaccinated with a uniquedose of recombinant measles virus has been collected after one month.Various dilutions of these sera have been injected in a final volume of0.1 ml in 6-week-old BALB/c mice and only 24 hours before inoculation of100 AP ₆₁UFF of strain IS-98-ST1 of WN virus (10 DL₅₀) intraperitoneally(see protocol in § B2).

The results of passive protection after two weeks of viral test are asfollows:

TABLE 2 Recombinant MV-WN sE induce antibodies that provide fullprotection against WNV encephalitis in BALB/c mice Passive transferMortality Day PBS/BSA (0.2%) 6\6 10 to 11 anti-WNV serum (1:10), 1 dose*0\6 NA anti-WNV serum (1:40), 1 dose 1\6 20 anti-MV (1:10), 1 dose 4\610 to 11 anti-MV-WN sE 10e4 (1:10), 1 dose 3\6 8 to 10 anti-MV-WN sE10e6 (1:10), 1 dose 0\6 NA anti-MV-WN sE 10e6 (1:40), 1 dose 0\6 NAanti-MV-WN sE 10e6 (1:100), 1 dose 3\6 10 to 11 (*Day −1 of viruschallenge)

To conclude, antibodies directed against WN-virus soluble glycoprotein Ehave the capacity to protect in vivo against WN-virus encephalitis. Thevaccination of CD46^(+/−) IFN-α/βR^(−/−) mice with a dose of 10⁶ DCIP₅₀of MV-WN sE virus as a unique injection is required to induce an anti-WNE humoral response on a four-week period of time which is capable ofprotecting against the disease by passive seroprotection. A minimalvolume of 2.5 μl of immune serum of mice vaccinated with MV-WN sE virus,is sufficient to provide a complete protection in adult BALB/c micetested with a lethal dose of WN-virus (i.e., a ratio of about 0.1 ml ofimmune serum/kg). It is noted that anti-lethal sera diluted to 1:10induce a partial protection (about 30%) against West Nile virusencephalitis.

Sera obtained in vaccinated CD46^(+/−) IFN-α/βR^(−/−) mice which havethen been boosted with a weak dose (10⁴ TCID50) will be tested for theircapacity to provide passive protection in BALB/c mice.

B.5. Viral Test on CD46^(+/−) IFN-α/βR^(−/−) Mice Vaccinated with MV-WNsE

CD46^(+/−) IFN-α/βR^(−/−) mice vaccinated 2 months after the 2injections of 10⁶ DCIP₅₀ of MV-WN sE virus, these injections being doneat 4 weeks internal have been tested with 100 AP ₆₁UFF of strainIS-98-ST1 of WN virus administered intraperitoneally.

The 2 mice vaccinated with standard measles virus died the 3rd day ofthe test. No morbidity or lethality was observed for mice vaccinatedwith MV-WN sE on the 7^(th) day of the test. To conclude,CD46^(+/−)IFN-α/βR^(−/−) mice immunized against soluble gpE of WN virusare protected against a lethal test dose of WN virus in the absence ofanti-viral activity of alpha-interferon.

B6. New Test of Anti-WN Vaccination with an Antigen Boost

Adult CD46^(+/−) IFN-α/βR^(−/−) mice are vaccinated on a 4 week periodof time with MV-WN sE virus at a dose of 10⁴ DCIP₅₀ which is proposedfor human and a boost with an antigen is carried out with purifiedpseudo-particles of WN-virus which are secreted by the cell lineMEF/3T3.Tet-Off/WN prME #h2.

BIBLIOGRAPHY

-   1. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P.    O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G.    Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M.    Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M.    McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control    of a mucosal challenge and prevention of AIDS by a multiprotein    DNA/MVA vaccine. Science. 292:69-74.-   2. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S.    Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G.    Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E.    Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000.    Human neutralizing monoclonal antibodies of the IgG1 subtype protect    against mucosal simian-human immunodeficiency virus infection. Nat    Med. 6:200-206.-   3. Barnett, S. W., S. Lu, I. Srivastava, S. Cherpelis, A. Gettie, J.    Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, A. Fong, C.    Buckner, A. Ly, S. Hilt, J. Ulmer, C. T. Wild, J. R. Mascola, and L.    Stamatatos. 2001. The ability of an oligomeric human    immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit    neutralizing antibodies against primary HIV-1 isolates is improved    following partial deletion of the second hypervariable region. J    Virol. 75:5526-5540.-   4. Binley, J. M., R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y.    Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, and J. P.    Moore. 2000. A recombinant human immunodeficiency virus type 1    envelope glycoprotein complex stabilized by an intermolecular    disulfide bond between the gp120 and gp41 subunits is an antigenic    mimic of the trimeric virion-associated structure. J Virol.    74:627-643.-   5. Boyer, J., K. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M.    Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. Williams, Y.    Refaeli, R. Ciccarelli, D. McCallus, L. Coney, and D. Weiner. 1997.    Protection of chimpanzees from high-dose heterologous HIV-1    challenge by DNA vaccination. Nature Medicine. 3:526-532.-   6. Burton, D. 1997. A vaccine for HIV type 1: the antibody    perspective. Proceedings of the National Academy of Sciences of the    United States of America. 94:10018-10023.-   7. Calain, P., and L. Roux. 1993. The rule of six, a basic feature    for efficient replication of Sendai virus defective interfering RNA.    J Virol. 67:4822-4830.-   8. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L.    Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious    molecular clone of an unusual macrophage-tropic and highly    cytopathic strain of human immunodeficiency virus type 1. J Virol.    66:7517-7521.-   9. Crotty, S., C. J. Miller, B. L. Lohman, M. R. Neagu, L.    Compton, D. Lu, F. X. Lu, L. Fritts, J. D. Lifson, and R.    Andino. 2001. Protection against simian immunodeficiency virus    vaginal challenge by using Sabin poliovirus vectors. J Virol.    75:7435-7452.-   10. Hoffman, T. L., C. C. LaBranche, W. Zhang, G. Canziani, J.    Robinson, I. Chaiken, J. A. Hoxie, and R. W. Doms. 1999. Stable    exposure of the coreceptor-binding site in a CD4-independent HIV-1    envelope protein. Proc Natl Acad Sci USA. 96:6359-6364.-   11. Hu, S., P. Polacino, V. Stallard, J. Klaniecki, S. Pennathur, B.    Travis, L. Misher, H. Kornas, A. Langlois, W. Morton, and R.    Benveniste. 1996. Recombinant subunit vaccines as an approach to    study correlates of protection against primate lentivirus infection.    Immunology Letters. 51:115-119.-   12. Karlsson, G. B., M. Halloran, J. Li, I. W. Park, R.    Gomila, K. A. Reimann, M. K. Axthelm, S. A. Iliff, N. L. Letvin,    and J. Sodroski. 1997. Characterization of molecularly cloned    simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte    depletion in rhesus monkeys. J Virol. 71:4218-4225.-   13. Kwong, P. D., R. Wyatt, S. Majeed, J. Robinson, R. W. Sweet, J.    Sodroski, and W. A. Hendrickson. 2000. Structures of HIV-1 gp120    envelope glycoproteins from laboratory-adapted and primary isolates.    Structure Fold Des. 8:1329-1339.-   14. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski,    and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope    glycoprotein in complex with the CD4 receptor and a neutralizing    human antibody. Nature. 393:648-659.-   15. Kwong, P. D., R. Wyatt, Q. J. Sattentau, J. Sodroski, and W. A.    Hendrickson. 2000. Oligomeric modeling and electrostatic analysis of    the gp120 envelope glycoprotein of human immunodeficiency virus. J    Virol. 74:1961-1972.-   16. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C.    VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S.    Frankel, Y. Lu, M. L. Robb, H. Katinger, and D. L. Birx. 1999.    Protection of Macaques against pathogenic simian/human    immunodeficiency virus 89.6PD by passive transfer of neutralizing    antibodies. J Virol. 73:4009-4018.-   17. Mascola, J. R., M. K. Louder, T. C. VanCott, C. V. Sapan, J. S.    Lambert, L. R. Muenz, B. Bunow, D. L. Birx, and M. L. Robb. 1997.    Potent and synergistic neutralization of human immunodeficiency    virus (HIV) type 1 primary isolates by hyperimmune anti-HIV    immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J    Virol. 71:7198-7206.-   18. Mascola, J. R., and G. J. Nabel. 2001. Vaccines for prevention    of HIV-1 disease. Immunology. 13:489-495.-   19. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B.    Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L.    Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal    transmission of a pathogenic HIV-1/SIV chimeric virus by passive    infusion of neutralizing antibodies. Nat Med. 6:207-210.-   20. Mrkic, B., B. Odermatt, M. Klein, M. Billeter, J. Pavlovic,    and R. Cattaneo. 1999. Lymphatic dissemination and comparative    pathology of recombinant measles viruses in genetically modified    mice. Journal of Virology. 74:1364-1372.-   21. Mrkic, B., J. Pavlovic, T. Rulicke, P. Volpe, C. J. Buchholz, D.    Hourcade, J. P. Atkinson, A. Aguzzi, and R. Cattaneo. 1998. Measles    virus spread and pathogenesis in genetically modified mice. J Virol.    72:7420-7427.-   22. Müller, U., U. Steinhoff, L. F. L. Reis, S. Hemmi, J.    Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of    type I and type II interferons in antiviral defense. Science.    264:1918-1921.-   23. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G.    Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing    epitope on gp41 of human immunodeficiency virus type 1. J Virol.    67:6642-6647.-   24. Naniche, D., G. Varior-Krishnan, F. Cervoni, T. F. Wild, B.    Rossi, C. Rabourdin-Combe, and D. Gerlier. 1993. Human membrane    cofactor protein (CD46) acts as a cellular receptor for measles    virus. J Virol. 67:6025-6032.-   25. Parren, P. W., M. C. Gauduin, R. A. Koup, P. Poignard, P.    Fisicaro, D. R. Burton, and Q. J. Sattentau. 1997. Relevance of the    antibody response against human immunodeficiency virus type 1    envelope to vaccine design. Immunol Lett. 57:105-112.-   26. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W.    Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin. 1996. A    chimeric simian/human immunodeficiency virus expressing a primary    patient human immunodeficiency virus type 1 isolate env causes an    AIDS-like disease after in vivo passage in rhesus monkeys. J Virol.    70:6922-6928.-   27. Sanders, R. W., L. Schiffner, A. Master, F. Kajumo, Y. Guo, T.    Dragic, J. P. Moore, and J. M. Binley. 2000. Variable-loop-deleted    variants of the human immunodeficiency virus type 1 envelope    glycoprotein can be stabilized by an intermolecular disulfide bond    between the gp120 and gp41 subunits. J Virol. 74:5091-5100.-   28. Schneider, H., K. Kaelin, and M. A. Billeter. 1997. Recombinant    measles viruses defective for RNA editing and V protein synthesis    are viable in cultured cells. Virology. 227:314-322.-   29. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E.    Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A.    Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A.    Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A.    Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R.    Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M.    Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M.    Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A.    Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E.    Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C.    Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral    vaccine vector elicits effective anti-immunodeficiency-virus    immunity. Nature. 415:331-335.-   30. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J.    Robinson, and J. Sodroski. 1993. Characterization of conserved human    immunodeficiency virus type 1 gp120 neutralization epitopes exposed    upon gp120-CD4 binding. J Virol. 67:3978-3988.-   31. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A.    Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore,    and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a    distinctive neutralization epitope on the gp120 glycoprotein of    human immunodeficiency virus type 1. J Virol. 70:1100-1108.-   32. Yannoutsos, N., J. N. ljzermans, C. Harkes, F. Bonthuis, C. Y.    Zhou, D. White, R. L. Marquet, and F. Grosveld. 1996. A membrane    cofactor protein transgenic mouse model for the study of discordant    xenograft rejection [published erratum appears in Genes Cells 1996    August; 1(8):785]. Genes Cells. 1:409-419.-   33. Griffin, D. 2001. Measles virus, P. 1401-1441. In D. Knipe    and P. Howley (ed.), Field's Virology, 4^(th) Edition, vol. 2.    Lippincott—Raven Publishers, Philadelphia.-   34. Hilleman, M. 2002. Current overview of the pathogenesis and    prophylaxis of measles with focus on practical implications.    Vaccine. 20:651-665.-   35. Radecke, F., P. Spielhofer, H. Schneider, K. Kaelin, M.    Huber, C. Dotsch, G. Christiansen, and M. A. Billeter. 1995. Rescue    of measles viruses from cloned DANN. Embdo J. 14: 5773-5784.-   36. Radecke, F., and Billeter. 1997. Reverse genetics meets the    nonsegmented negative-strand RNA viruses. Reviews in Medical    Virology. 7:49-63.-   Singh, M., R. Cattaneo, and M. A. Billeter. 1999. A recombinant    measles virus expressing hepatitis B virus surface antigen induces    humoral immune responses in genetically modified mice. J. Virol. 73:    4823-4828.-   Spielhofer, P., T. Bachi, T. Fehr, G. Christiansen, R. Cattaneo, K.    Kaelin, M. Billeter, and H. Naim. 1998. Chimeric measles viruses    with a foreign envelope. J. Virol. 72: 2150-2159.-   39. Srivastava, I., K. Vandorsten, L. Vojtech, S. Barnett, and L.    Stamatos. 2003. Changes in the immunogenic properties of soluble    gp140 human immunodeficiency virus envelope constructs upon partial    deletion of the second hypervariable region. J. Virol. 77:2310-2320.-   40. Parks, C. L., R. A. Lerch, P. Walpita, M. S. Sidhu, and S. A.    Udem. 1999. Enhanced measles virus cDNA rescue and gene expression    after heat shock. J. Virol. 73: 3560-3566.-   41. Karber, G. 1931. Breitag zur kollektiven Behandlung    pharmakologischer Reihenversuche. Arch Exp Path Pharmak. 162:    480-483.-   42. Burrer, R., D. Salmon-Ceron, S. Richert, G. Pancino, G.    Spiridon, S. Haessig, V. Rogues, F. Barre-Sinoussi, A. M. Aubertin,    and C. Moog. 2001. Immunoglobulin G (IgG) and IgA, but also    nonantibody factors, account for in vitro neutralization of human    immunodeficiency virus (HIV) type 1 primary isolates by serum and    plasma of HIV-infected patients. J Virol. 75: 5421-5424.-   43. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F.    Clavel 1994. HIV-1 reverse transcription. A termination step at the    center of the genome. J Mol Biol. 241:651-662.-   44. Coeffier, E., J. Clement, V. Cussac, N. Khodaei-Boorane, M.    Jehanno, M. Rojas, A. Dridi, M. Latour, R. El Habib, F.    Barré-Sinoussi, M. Hofnung, and C. Leclerc. 2001. Antigenicity and    immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into    permissive sites of the MalE protein. Vaccine. 19:684-693.-   45. Mascola, J. R., M. K. Louder, T. C. VanCott, C. V. Sapan, J. S.    Lambert, L. R. Muenz, B. Bunow, D. L. Birx, and M. L. Robb. 1997.    Potent and synergistic neutralization of human immunodeficiency    virus (HIV)) type 1 primary isolates by hyperimmune anti-HIV    immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J    Virol. 71: 7198-7206.-   45. Eckhart, L., W. Raffelberger, B. Ferko, A. Klima, M.    Purtscher, H. Katinger, and F. Rüker. 1996. Immunogenic presentation    of a conserved gp41 epitope of human immunodeficiency virus type I    on recombinant surface antigen of hepatitis B. virus. J. Gene.    Virol. 77: 2001-2008.-   46. Ho, J., K. MacDonald, and B. Barber. 2002. Construction of    recombinant targeting immunogens incorporating an HIV-1 neutralizing    epitope into sites of differing conformational constrain. Vaccine.    20: 1169-1180.-   47. Liang, X., S. Munshi, J. Shendure, Mark, M. Davies, D. Freed, D.    Montefiori, and J. Shiver. 1999. Epitope insertion into variable    loops of HIV-1 gp120 as a potential means to improve immunogenicity    of viral envelope protein. Vaccine. 17: 2862-2872.-   48. Jeffs, S., C. Shotton, P. Balfe, and J. McKeating. 2002.    Truncated gp120 envelope glycoprotein of human immunodeficiency    virus 1 elicits broadly reactive neutralizing immune response. J.    Gen. Virol. 83: 2723-2732.-   49. Kwong, P., and e. al. 2002. HIV evades antibody-mediated    neutralization through conformational masking of receptor-binding    sites. Nature. 420-678-682.-   50. Dilraj. A., F. T. Cutts, J. F. de Castro, J. G. Wheeler, D.    Brown, C. Roth, H. M. Coovadia, and J. V. Benett. 2000, Lancet.    355:798-803.-   51. Desprès et al, 1993. Virology 196: 209-219-   52. Mashimo et al. 2002. PNAS. USA 99: 11311-11316-   53. Lucas et al. 2003. Immunol. Cell. Biol. 81(3): 230-6.

1-51. (canceled)
 52. A method of inducing an immune response against anRNA virus in a host, comprising administering to the host a compositioncomprising (i) a recombinant measles virus expressing a heterologousamino acid sequence, or a recombinant measles virus expression vectorfor expressing a heterologous amino acid sequence, and (ii) anacceptable vehicle, wherein said virus or vector comprises a sequencecomprising: A) a nucleotide sequence encoding the full lengthantigenomic (+)RNA strand of a measles virus; B) a T7 promoter sequencecomprising a GGG motif at its 3′ end, operably linked to the nucleotidesequence of A; C) a hammerhead ribozyme sequence located adjacent to theGGG motif at one end and adjacent to the first nucleotide of thenucleotide sequence encoding the full length anti-genomic (+)RNA strandof the measles virus strain at the other end; D) a T7 terminatorsequence operably linked to the nucleotide sequence of A; E) thesequence of a hepatitis delta virus ribozyme located adjacent to thelast nucleotide of the nucleotide sequence encoding the full lengthanti-genomic (+)RNA strand of the measles virus; and F) a heterologouscoding sequence encoding a heterologous amino acid sequence comprisingan antigen of a heterologous RNA virus.
 53. The method of claim 52,wherein the measles virus is a measles virus vaccine strain.
 54. Themethod of claim 52, wherein the RNA virus is a flavivirus or aretrovirus.
 55. The method of claim 52, wherein the RNA virus is not aflavivirus or a retrovirus.
 56. The method of claim 52 wherein theheterologous coding sequence is cloned between the P and M genes of themeasles virus.
 57. The method according to claim 52, wherein theheterologous coding sequence is cloned between the H and L genes of themeasles virus.
 58. The method according to claim 52, wherein thecomposition is administered in a prime-boost administration regime. 59.The composition according to claim 52, wherein the composition isadministered through subcutaneous (s.c.) or intraperitoneal (i.p.)injection.
 60. The method of claim 53, wherein the RNA virus is not aflavivirus or a retrovirus.
 61. The method of claim 60 wherein theheterologous coding sequence is cloned between the P and M genes of themeasles virus.
 62. The method according to claim 60, wherein theheterologous coding sequence is cloned between the H and L genes of themeasles virus.
 63. The method according to claim 60, wherein thecomposition is administered in a prime-boost administration regime. 64.The composition according to claim 60, wherein the composition isadministered through subcutaneous (s.c.) or intraperitoneal (i.p.)injection.
 65. An expression vector for producing an infectiousrecombinant Schwarz strain of measles virus comprising: A) thenucleotide sequence encoding the full length antigenomic (+)RNA strandof the measles virus Schwarz strain (from position 83 to position 15976of SEQ ID NO: 82); B) a T7 promoter sequence comprising a GGG motif atits 3′ end, operably linked to the nucleotide sequence of A; C) ahammerhead ribozyme sequence (from position 29 to position 82 of SEQ IDNO: 82) located adjacent to the GGG motif at one end and adjacent to thefirst nucleotide of the nucleotide sequence encoding the full lengthanti-genomic (+)RNA strand of the measles virus Schwarz strain at theother end; D) a T7 terminator sequence operably linked to the nucleotidesequence of A; E) the sequence of a hepatitis delta virus ribozymelocated adjacent to the last nucleotide of the nucleotide sequenceencoding the full length anti-genomic (+)RNA strand of the measles virusSchwarz strain; and F) a heterologous coding sequence encoding aheterologous amino acid sequence.
 66. A method for generating infectiousrecombinant Schwarz strain of measles virus, comprising: (A) providingan expression vector for producing the Schwarz strain of measles virus,wherein the expression vector comprises (i) the nucleotide sequenceencoding the full length antigenomic (+)RNA strand of the measles virusSchwarz strain (from position 83 to position 15976 of SEQ ID NO: 82);(ii) a T7 promoter sequence comprising a GGG motif at its 3′ end,operably linked to the nucleotide sequence of (i); (iii) a hammerheadribozyme sequence (from position 29 to position 82 of SEQ ID NO: 82)located adjacent to the GGG motif at one end and adjacent to thenucleotide sequence of (i) at the other end; (iv) a T7 terminatorsequence operably linked to the nucleotide sequence of A; (v) thesequence of a hepatitis delta virus ribozyme located adjacent to thelast nucleotide of the nucleotide sequence encoding the full lengthanti-genomic (+)RNA strand of the measles virus Schwarz strain; (vi) aheterologous coding sequence encoding an amino acid sequence of aheterologous antigen; (B) transfecting helper cells with the expressionvector of (A), wherein the helper cells express a heterologousDNA-dependent RNA polymerase and N, P, and L proteins of measles virus;(C) maintaining the transfected helper cells under conditions suitablefor production of Schwarz strain measles viral particles; (D) passagingthe viral particles in cells suitable for the passage of the Schwarzstrain; and (E) recovering infectious recombinant Schwarz strain measlesvirus particles.
 67. An expression vector for producing an infectiousrecombinant live-attenuated measles virus comprising: A) a nucleotidesequence encoding a full length antigenomic (+)RNA strand of thelive-attenuated measles virus; B) a T7 promoter sequence comprising aGGG motif at its 3′ end, operably linked to the nucleotide sequence ofA); C) a hammerhead ribozyme sequence located adjacent to the GGG motifat one end and adjacent to the first nucleotide of the nucleotidesequence encoding the full length anti-genomic (+)RNA strand of themeasles virus at the other end; D) a T7 terminator sequence operablylinked to the nucleotide sequence of A); E) a sequence of a hepatitisdelta virus ribozyme located adjacent to the last nucleotide of thenucleotide sequence encoding the full length anti-genomic (+)RNA strandof the measles virus; and F) a heterologous coding sequence encoding aheterologous amino acid sequence.
 68. A method of making an immunogeniccomposition, comprising: providing (i) a recombinant measles virusexpressing a heterologous amino acid sequence, or a recombinant measlesvirus expression vector for expressing a heterologous amino acidsequence, wherein said virus or vector comprises a sequence comprising:A) a nucleotide sequence encoding the full length antigenomic (+)RNAstrand of a measles virus; B) a T7 promoter sequence comprising a GGGmotif at its 3′ end, operably linked to the nucleotide sequence of A; C)a hammerhead ribozyme sequence located adjacent to the GGG motif at oneend and adjacent to the first nucleotide of the nucleotide sequenceencoding the full length anti-genomic (+)RNA strand of the measles virusstrain at the other end; D) a T7 terminator sequence operably linked tothe nucleotide sequence of A; E) the sequence of a hepatitis delta virusribozyme located adjacent to the last nucleotide of the nucleotidesequence encoding the full length anti-genomic (+)RNA strand of themeasles virus; and F) a heterologous coding sequence encoding aheterologous amino acid sequence comprising an antigen of a heterologousRNA virus; and combining the recombinant measles virus expressing aheterologous amino acid sequence, or a recombinant measles virusexpression vector for expressing a heterologous amino acid sequence,with (ii) an acceptable vehicle, to thereby provide the immunogeniccomposition.